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Migraine is a common and disabling neurological disorder. The postdrome phase of migraine, is 
poorly defined and studied, in comparison to the preceding phases. It has also not been defined in 
the International Classification of Headache disorders. Hence there exists a vital need to understand 
the pathophysiology involved in this phase. 
 
No imaging study has evaluated the postdrome phase. Preceding phases of migraine have been 
studied, but with PET imaging as the functional imaging modality. However, there are various 
limitations of PET which pose several logistical challenges in studying the postdrome phase. Arterial 
Spin Labelling (ASL) MRI is a novel MRI technique that measures tissue perfusion without ionizing 
radiation.  
 
Previous diary studies have shown the extent of postdrome amongst migraineurs to vary from 61-
80%. A clinical audit carried out within our clinical cohort of patients showed that 86% of subjects 
reported postdrome symptoms. 
 
The primary hypothesis behind the ASL MRI study is that, brain areas with increased neuronal 
activations in the premonitory phase, remain persistently activated in the postdrome phase. The 
reasoning behind this is, the broadly similar nature of symptoms that patients complain of, in both 
these phases. A nitroglycerin induced migraine model was applied to study the activations.  
 
In this prospective imaging study involving 16 subjects, voxel based analysis showed a near global 
reduction in rCBF in the postdrome phase compared to the premonitory phase with a peak 
reduction over the left superior temporal gyrus (P<0.001).  
 
This study has shown that the biology of neural activations in the premonitory and postdrome phase 
are different and not due to persistent activation of similar neural networks. The symptoms 
experienced by subjects in the postdrome are associated with a significant, near global reduction in 
cerebral blood flow. In chapter 7, a subgroup analysis was carried out to see if there was any 
seasonal variation to nitroglycerin induced migraine. The analysis showed that the triggering rates 
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Migraine is a common and disabling disorder affecting an estimated 12% of the world population 
(2015). Four non-obligatory phases have been described in migraine. The postdrome phase is the 
least studied amongst the various phases of migraine and described only recently (Selby, 1983; 
Kelman, 2006; Bose and Goadsby, 2016). The various phases of migraine often overlap in 
symptomatology but generally comprise of specific symptoms prior to the onset of head pain such 
as thirst, cravings and yawning, which are collectively called the premonitory symptoms (Giffin et al., 
2003), the migraine aura, which is characterised by brief transient focal neurological symptoms and 
only occurs in one-third of patients, the migraine headache or attack phase when a throbbing 
headache is experienced and finally, the postdrome phase, a combination of various non-headache 
symptoms that patients often experience after the throbbing headache has ceased, and before they 
return to back to normal function (Giffin et al., 2016). 
Premonitory symptoms occur prior to the onset of migraine headache, and can include symptoms 
like fatigue, excessive yawning and excessive micturition. An electronic diary study by Giffin et al, 
had previously shown that premonitory symptoms are highly predictive of an impending attack and 
there tends to be a large amount of inter-individual variability but not intra-individual variability in 
these symptoms (Giffin et al., 2003). The postdrome phase of migraine has been largely neglected in 
the literature, and tends to comprise of cognitive difficulties, fatigue and poor attention (Blau, 1991; 
Kelman, 2006; Quintela et al., 2006; Giffin et al., 2016) . The paucity of literature surrounding this 
phase and its significant burden for patients, in terms of returning to normal function, highlights the 
importance of developing a greater understanding of the mechanisms that underlie this phase (Ng-
Mak et al., 2011). In a cohort of 827 patients, Kelman found that 68% described postdrome 
symptoms (Kelman, 2006). A prospective electronic study by Giffin et al., noted that 55% of subjects 
returned to normal function within 6 hours whereas 7% required over 24 hours to return to normal 
(Giffin et al., 2016). No imaging study has looked into the postdrome phase. Given that there are 
some similar symptoms experienced by subjects in the premonitory phase and postdrome phase 
(Giffin et al., 2003; Giffin et al., 2016), it seems pertinent to know whether this is the consequence of 
activation of similar brain areas. Understanding the pathophysiology involved in the postdrome will 
ultimately lead to an enhanced understanding of the underlying central nervous system mechanisms 
and potential new therapeutic strategies. 
One of the earliest observations that allude to the postdrome, was made by Liveing who 






that sleep resolved migraine attacks in some patients (Liveing, 1872). Selby was amongst the few 
neurologists who designated the postdrome as a characteristic feature of migraine. In his book 
‘Migraine and its variants’, Selby used the term ‘post-headache phase’ to describe what is now 
called the postdrome phase. He described it as the “anticlimactic act of the migraine drama where 
pain and nausea has settled down but patients are left with a difficult to describe prostration and 
malaise yet typical of migraine” (Selby, 1983). One of the earliest authors to speculate on the 
pathophysiological basis of the postdrome was Blau who suggested that the postdrome may be due 
to a slow decline in migraine processes or, potentially an inverse mechanism with respect to the 
premonitory symptoms (Blau, 1991) .  
 
Novel neuroimaging modalities have pushed the frontiers in the understanding of neurological 
disorders and have also shed further light into the possible links between brain structures and brain 
networks that could be involved in the pathophysiology of disease. Functional imaging, including 
functional MRI (fMRI) and positron emission tomography (PET), have been increasingly used in 
migraine and other pain states and has alluded to areas of brain activation that are thought to be 
key structures in the initiation and propagation of the headache and pain states (Maniyar et al., 







1.1 Migraine- A brief historical perspective 
 
Headache has been a part and parcel of human experience since antiquity. The earliest document 
descriptions of migraine appear in ancient Egyptian papyrus and Babylonian cuneiform tablets over 
6000 years ago (Walsh et al., 1982; Weatherall, 2012). The descriptions of migraine and the varying 
treatments carried out were just as diverse as the various cultures from pre-historic times. Perhaps 
the diversity in treatments of headache disorders carried out around the world, even in this current 
age, depend on various cultural, social and geographical traditions (Levin, 2008; Finger et al., 2010). 
Certain accounts narrated in ancient religious texts like the Old Testament, could be attributed to 
migraine due to some key pertinent aspects (Borsook, 2012). 
 
The earliest documentation of the migraine aura comes from the writings of the Hippocratic School 
of medicine 200 BC (Borsook, 2012) . The prominent Greek physician, Galen of Pergamon first used 
the term ‘hemicrania’ which later gave rise to the term migraine. Aretaeus of Cappadocia, also a 
prominent Greek physician, wrote about headaches in the early second century and divided it into 
three types namely, short lived, persistent or recurrent (Borsook, 2012). This was the first clear 
headache classification recorded (Martelletti et al., 2011). 
 
The Islamic medicine writers of the 11th to 13th centuries reinforced the ideas of the earlier Greco-
Roman physicians. The renowned Persian physician of the time, Avicenna made significant 
contributions to neurology including in the field of headache and migraine (Zargaran et al., 2016). 
 
Thomas Willis (1621-1675) can be arguably called the father of the modern era of neurology. In his 
book De Anima Brutorum, he dedicates two chapters to the topic of headache. His work dealt with 
headache etiology, mechanisms and classifications. It was heavily based on his ‘animal spirits’ 
concept (Eadie, 2003). Thomas Willis may have been the first to hypothesize the neurovascular 
theory of migraine by speculating that it was caused by increased arterial blood flow in the meninges 
(Willis, 1668; Eadie, 2003; Akkermans, 2015). 
 
Premonitory symptoms of migraine have been long recognized (Gowers, 1970). The postdrome 
phase as an entity is a relatively newly described phase of migraine (Selby, 1983). To get a historical 
perspective regarding the neural activations in these phases, one must start with the vascular versus 
neurogenic theory, which is an oft-recurring theme amongst neurologists and has been debated as 






British neurologists Peter Wallwork Latham (Latham, 1872), who favoured the ‘vasomotor theory’ 
and Edward Liveing (Liveing, 1872) who favoured the ‘nerve storm’ theory. These theories can be 
considered the prototypical vascular and neurogenic theories of migraine pathogenesis. Various 
contemporary neurologists of the time, like Gowers (Gowers and Princess Marina Hospital. Library, 
1886), undermined the theory proposed and terminologies used by Liveing (Gowers, 1906; 
Weatherall, 2012). Furthermore, Harold Wolff a 20th century pioneer in headache research, 
performed ground breaking research further promoting the vascular theory of migraine (Akkermans, 
2015).  
 
Over time, with the help of various scientific technological breakthroughs, it has been shown that 
migraine is initiated by a primary neuronal activation that sets of a cascade of changes intracranially 
and extracranially that account for the symptoms (Cutrer, 2006). Vascular changes like extracranial 
arterial dilatation that was hypothesised to be the cause of pain in patients suffering from migraine 
without aura (Tunis and Wolff, 1953) can be considered an epiphenomenon and not the primary 
trigger (Amin et al., 2013). Advances in the understanding of the key brain areas involved in migraine 
pathogenesis, using functional imaging techniques have helped to characterise further the 
premonitory and headache phases of migraine (Maniyar et al., 2014a). The evolving improvement in 
our understanding of migraine-specific anatomical pathways and molecular pathways have led to 
the development of novel treatments strategies with furthermore on the horizon (Diener et al., 
2015; Karsan and Goadsby, 2015; Goadsby et al., 2017). Therapeutic agents targeting calcitonin 
gene-related peptide receptor, 5-HT1F receptor and neuromodulatory options offer promise in the 
treatment of migraine (Karsan et al., 2017; Nazia Karsan, 2017) and have ushered in, a new era in 
migraine management.  
 
As science progresses, from the ancient Egyptian civilization to the present times, we are now in a 
unique position to study what happens to the brain during different phases of migraine including the 
postdrome, using innovative technological advances. In time, as physicians and scientists, we hope 







1.2 Migraine anatomical considerations and pathophysiology 
 
Migraine is thought to be due to a primary brain dysfunction. Neuronal activation leads to a cascade 
of changes intracranially and extracranially that account for the symptoms. Dysfunction of 
subcortical structures may modulate the perception and activation of the trigeminovascular system.  
 
1.2.1 Key structures 
 
The brain itself is largely insensitive to pain. The key structures involved in the perception of 
headache include the large intracranial vessels and dura mater (Feindel et al., 1960), the peripheral 
terminals of the trigeminovascular system that innervate these structures , the caudal portion of the 
trigeminal nucleus, which extends into the dorsal horns of the upper cervical spinal cord and 
receives input from the first and second cervical nerve roots (the trigeminocervical complex) and the 
pain modulatory systems in the brain that receive input from trigeminal nociceptors (Feindel et al., 
1960; McNaughton FL, 1977; Akerman et al., 2011). 
 
 
Figure 1. Neuronal Pathways involved in Migraine pathophysiology 
Sensory afferents from the head and neck travel as trigeminal afferents through the trigeminal 
ganglion (TG) or as afferents from the greater occipital nerve through the cervical ganglion (CG), 
and synapse on second-order neurons in the trigeminocervical complex (TCC). Neurons in the TCC 






the thalamus. There is also a reflex connection from neurons of the TCC to neurons in the superior 
salivatory nucleus (SuS) in the pons, and from there to the cranial vasculature through the 
sphenopalatine ganglion (SPG; pterygopalatine), which provides parasympathetic outflow to the 
cranium. Activation of the trigeminal autonomic reflex contributes to the cranial autonomic 
symptoms of many primary headaches. Second-order neurons in the TCC also send direct 
projections to various structures in the brainstem, including the locus coeruleus (LC) and 
periaqueductal grey (PAG), and to higher structures including the hypothalamus and thalamus, 
which in turn send ascending signals to the cortex. There are also descending projections from the 
cortex to thalamic and hypothalamic structures, as well as to the LC. Descending modulation of 
TCC neurons takes place via hypothalamic nuclei, including the A11 dopaminergic nucleus, and 
there is direct descending modulation of TCC neurons from projections from the PAG that pass 
through the rostral ventromedial medulla (RVM). Trigeminal sensory connections to the periphery 
and the TCC (shown by purple fibres), the parasympathetic connection to the head and orofacial 
vasculature (shown by pink fibres) and the occipital nerve projection to the peripheral face and 
neck, and central projections to the TCC (shown by light blue fibres) are included. Ascending 
connections through the quintothalamic tract and to the SuS (shown by dark blue fibres) and the 
likely ascending projections to the LC, PAG and hypothalamic nuclei (shown by dashed lines) are 
shown. The descending projections to the TCC that control its activity (shown by red fibres) are 
also indicated. With kind permission (Akerman et al., 2011) (See Page 142 for permissions to use 
figure). 
 
Neuroimaging studies have pointed to the hypothalamus as the key driving force for migraine and 
hypothalamic activation has been noted even before the onset of headache (Maniyar et al., 2014a; 
Schulte and May, 2016b). What causes the hypothalamic and other brain areas to be activated in 
migraine, is not fully understood. There are bidirectional connections between the key brainstem 
areas activated in migraine and diencephalic areas involved in pain processing like the hypothalamus 
and the thalamus (Davis and Dostrovsky, 1988; Malick and Burstein, 1998; Malick et al., 2000; 
Burstein et al., 2010; Robert et al., 2013).  
 
1.2.2 The role of neuropeptides 
 
Various neuropeptides have been postulated to play a dominant role in the migraine 
pathophysiology. Calcitonin gene-related peptide (CGRP) appears to be a key molecule involved and 
studies have shown that CGRP levels can increase during migraine attacks (Goadsby et al., 1990; 
Goadsby and Edvinsson, 1993b) and migraine can be induced by giving a CGRP infusion (Lassen et 
al., 2002). Therapeutic interventions that target CGRP and its receptors look promising in the 
management of migraine (Olesen  et al., 2004; Connor et al., 2011; Bigal et al., 2015; Goadsby et al., 
2017). Other key neuropeptides speculated to play a dominant role in the pathophysiology of 
migraine include vasoactive intestinal peptide (VIP) (Dickson and Finlayson, 2009; Couvineau and 
Laburthe, 2012), nociceptin (NOP)(Bartsch et al., 2002; Ertsey et al., 2005) pituitary adenylate-






(NPY)(Goadsby and Edvinsson, 1993a), substance P (SP)(Chang et al., 1971; Moskowitz, 1993), 
somatostatin (SST)(Vecsei and Widerlov, 1988; Vecsei et al., 1992; Bartsch et al., 2005) and the 
orexins (OXs)(Cady et al., 2014; Hoffmann et al., 2015). It is thought that neuropeptides like CGRP, 
PACAP and PGI2 may trigger a migraine cascade at a molecular level by releasing nitric oxide (Lassen 
et al., 2002; Schytz et al., 2010). Though it is known that these dominant neuropeptides play a key 
role in the migraine process, it remains to be elucidated as to their precise molecular cascade that 
maybe responsible for a migraine attack.  
 
1.2.3 Cortical spreading depression 
 
Cortical spreading depression (CSD) is a wave of neuronal and glial depolarization that maybe 
induced either physically or by chemical stimuli. This wave, once initiated, spreads across the 
cerebral cortex autonomously. The speed at which this wave spreads, is similar to the observed 
speed of the migraine aura (Lashley, 1941; Leao, 1947; Lauritzen, 1994) and hence thought to be the 
experimental phenomenon linked to migraine aura. The concept was first highlighted by Leao and 
was a serendipitous observation whilst he was working on his PhD thesis at Harvard. Leao first 
demonstrated the phenomenon in rabbits (Leao, 1947). Currently, cortical spreading depression is 
thought to cause the aura of a migraine attacks, and some think, activate trigeminal nerve afferents 
and also considered to alter blood-brain barrier permeability by virtue of activation of matrix 
metalloproteinases and its upregulation (Moskowitz et al., 1993; Hadjikhani et al., 2001; Gursoy-
Ozdemir et al., 2004).  
 
There was a lot of scepticism regarding the concept of cortical spreading depression being a 
migraine trigger when it was raised first (Takano and Nedergaard, 2009). Experimental data (Gursoy-
Ozdemir et al., 2004) and functional neuroimaging (Hadjikhani et al., 2001) have helped to allay the 
initial scepticism. In a study using blood oxygenation level-dependent (BOLD) MRI imaging, 
Hadjikhani and colleagues showed brain activation changes that suggested the presence of cortical 
spreading depression (CSD) in human subjects and thereby proposed that CSD generates aura in the 
human visual cortex. Whether there is a link between CSD and brain activations during the 







1.2.4 Direct clinical evidence  
The first direct clinical evidence that showed involvement of brainstem structures in migraine 
generation was reported by Raskin and colleagues (1987). Patients (n=175) underwent implantation 
of an electrical pain stimulation system, commonly for intractable lower back ache. The electrodes 
were implanted in the somatosensory area of the thalamus or the periaqueductal gray region (PAG). 
Out of these 175 patients, 15 who did not typically suffer from headaches before, developed 
headache with what the authors describe as ‘florid migrainous’ features. Of these subjects, 13 had 
electrodes inserted into the periaqueductal gray region and the headaches persisted following 
explantation of the electrodes (Raskin et al., 1987). Subsequently, activation of the ventrolateral 
periaqueductal gray (vlPAG) was shown by PET imaging during a spontaneous migraine attack 
(Weiller et al., 1995). Activation of the periaqueductal gray has also been shown using PET imaging 
in NTG triggered migraine attacks (Maniyar et al., 2014a).  
 
Another key brain structure involved in the migraine pathophysiology is the hypothalamus as shown 
by various functional imaging studies (Denuelle et al., 2007; Maniyar et al., 2014a). Several 
symptoms seen in the premonitory phase of  migraine like sleepiness (Goder et al., 2001) reduced 
alertness (Dalkvist et al., 1984), mood changes, food craving, thirst (Blau, 1980; Giffin et al., 2003) 
could be attributed to hypothalamic activation (Rao and Pearce, 1971) . Due to the broadly similar 
nature of symptoms seen in the postdrome, it would be vital to find out if the symptoms are 
associated with persistent hypothalamic activation. Other key areas found to be activated in the 
premonitory phase include the midbrain tegmental area, dorsal pons and cortical areas like occipital, 








1.2.5 The migraine postdrome: A definition 
 
For the purpose of the study, the migraine postdrome was defined as the time between headache 
resolution and feeling completely back to normal. Headache resolution was defined as cessation of 
troublesome throbbing headache (Giffin et al., 2016). While individual attack profiles vary amongst 
individuals, the average postdromal duration has been seen to vary from 18 – 25 hours. This 
prolonging of abnormal behavioural states thus significantly prolongs the burden of migraine and 
represents a key disabling attack feature (Blau, 1991; Ng-Mak et al., 2011). A factor that has 
profound relevance to the lack of understanding and research into the postdrome phase, is the 
absence of a definition in the International Classification of Headache disorders. (2013). Hence it is 
crucial to have a classification to drive further research into this important but neglected phase of 
migraine.  
 
1.2.6 Key structures that may be involved in the postdrome 
 
The dysfunction of neuromodulatory structures in the brainstem is thought to be a core component 
in the pathophysiology of migraine (Akerman et al., 2011). As the major noradrenergic nucleus, the 
locus coeruleus has a vital role in the regulation of cortical function and is known to modulate 
responses to afferent traffic (Aston-Jones and Cohen, 2005). This area has been shown to be 
activated during acute migraine attacks in positron emission tomography (PET) studies (Afridi et al., 
2005; Weiller et al., 1995) and could play a dominant role in the postdrome. 
 
There is evidence to support the view that the brain in migraineurs is hyperexcitable to a variety of 
stimuli. This suggests that neuronal depolarisation, which is the presumed initiating event in 
migraine aura and possibly in migraine without aura, is more easily triggered (Mayevsky et al., 1996; 
Strong et al., 2002; Fabricius et al., 2006). Due to the hyperexcitability, a lower level of transcranial 
magnetic stimulation of the occipital cortex is required to produce visual phosphenes in migraineurs 
compared with non-migraineurs (Olesen et al., 1981; Ebersberger et al., 2001; Hadjikhani et al., 
2001). Genetic mutations can increase neuronal excitability through a variety of mechanisms 
(Ophoff et al., 1996; Goadsby, 2007; Goadsby et al., 2009). The cortical excitability may indicate 
chronicity process in the disease (Stankewitz and May, 2009).  
 
Previous studies have shown activations of posterolateral hypothalamus, midbrain tegmental area, 






regions in the premonitory phase (Maniyar et al., 2014a). The symptoms that patients complain of 
are broadly similar in the premonitory and postdromal phase (Giffin et al., 2003; Giffin et al., 2016). 
Based on the similarity of symptoms, one can hypothesize that there may be a shared neural 
network that is active in the postdrome and premonitory phases. It will further our understanding of 
the migraine pathophysiology when we know which brain areas are activated for the onset and 
development of the postdromal symptoms and if indeed they are similar to the networks known to 
be activated in the premonitory phase.  
 
Another potential neuroanatomical explanation for postdrome symptoms is diffuse cortical and 
subcortical involvement given the multitude of symptoms patients describe in the postdrome 
(Kelman, 2006; Quintela et al., 2006; Pascual, 2011; Bose and Goadsby, 2016; Giffin et al., 2016). 
Blau suggested that the involvement of the whole brain , especially the frontal lobes and the 
hypothalamus as vital structures in the pathophysiology of the postdrome after evaluating 
postdrome symptoms within his cohort of subjects (Blau, 1991).   
 
Hence due to the multifaceted presentation of postdrome symptoms, any number of neural 
networks could potentially be involved and it is vital to study and identify the key regions that are 







1.3 NTG triggered human migraine model 
 
There are several practical difficulties in studying spontaneous migraine mainly due to various 
logistical challenges. The unpredictability of the attacks means that the subject may not be in the 
vicinity of the research centre whilst having a migraine attack. Secondly, if the subject does get an 
attack, there may be difficulties in travelling to the research centre whilst in pain or whilst having 
some of the other associated symptoms like photophobia or nausea. Finally, the window of 
opportunity to capture the brain activations using functional imaging maybe lost in transit.  
 
NTG was first synthesized by the Italian chemist Ascanio Sobrero in 1847, whilst he was working 
under Théophile-Jules Pelouze, a renowned chemist of the time, at the University of Turin. At the 
time of discovery, Sobrero observed the ability of NTG to induce a violent headache (Tfelt-Hansen 
and Tfelt-Hansen, 2009; Schytz et al., 2010). Alfred Nobel, who was a colleague of Sobrero, realized 
the explosive potential of NTG and utilized it in the invention of dynamite. Dynamite was a 
commercial success and dynamite factories sprung up all over the world. Workers in these factories 
were frequently noted to have a headache which was then thought to be NTG induced (Tfelt-Hansen 
and Tfelt-Hansen, 2009). 
 
Based on these observations, various groups explored migraine provocation models using NTG. 
Models using oral (Schnitker and Schnitker, 1947), percutaneous (Dalsgaard-Nielsen, 1949) and 
sublingual (Peters, 1953) NTG preparations were tried with varying successes. The wide range of 
bioavailability of these models had the effect of large inter subject variability of symptoms (Tfelt-
Hansen and Tfelt-Hansen, 2009). In order to limit this wide variability, the concept of intravenous 
infusion of NTG (Iversen et al., 1989) was tested and has since become the most widely used human 
migraine provocation model (Thomsen et al., 1994; Christiansen et al., 1999; Afridi et al., 2004b; 
Sances et al., 2004; Afridi et al., 2005a). 
 
The exact mechanisms through which NTG induces a migraine is not known. The widely accepted 
understanding is that NTG gets converted to nitric oxide in the body. This in turn activates 
intracellular soluble guanylate cyclase and catalyses the formation of cyclic guanosine 
monophosphate (cGMP). The upregulation of intracellular cGMP may trigger off a cascade of 
changes centrally and peripherally, leading to migraine though there is no firm evidence at the 







NTG triggering induces a biphasic response in migraine patients and in healthy subjects with a family 
history of migraine. There is an initial NTG induced non-specific featureless headache which is 
dissimilar to the subject’s usual migraine and is short lasting. Later on, subjects develop a delayed 
headache that is similar to their usual migraine attacks. Studies have shown that a migraine attack 
maybe be triggered in 75% of migraineurs using NTG (Afridi et al., 2004b). Clinically, spontaneous 
and triggered migraine attacks are indistinguishable (Afridi et al., 2004b) and functional imaging 
studies in spontaneous migraine (Afridi et al., 2004a; Schytz et al., 2010; Schulte and May, 2016b) 
and NTG induced migraine attacks show similar areas of neural activation (Afridi et al., 2005c; 
Maniyar et al., 2014a). 
 
NTG triggering is therefore an appropriate human migraine provocation model as waiting for 
subjects’ spontaneous attacks would be impractical. This model has been successfully used in the 
past to study brain activations during premonitory phase and migraine, using PET imaging  (Afridi et 
al., 2004b; Maniyar et al., 2014a; Maniyar et al., 2014b). The findings of such studies have shown 
that triggering with NTG produces headache and premonitory symptoms which are phenotypically 
similar to subjects’ spontaneous attacks in a reproducible manner and it is uncommon for aura to be 
triggered using this method (Afridi et al., 2004b).  
 
Functional imaging of NTG triggered migraine attacks, gives us the unique opportunity to study 
cerebral blood flow alterations in the brain to assess if similar brain structures are being activated 







1.4 Migraine functional imaging 
 
Understanding the key brain areas involved in migraine should help unravel the pathophysiology 
further and potentially identifying newer therapeutic targets. Previous functional imaging studies 
have advanced our knowledge regarding the pathophysiology of migraine (Afridi et al., 2005c; 
Maniyar et al., 2014a; Schulte and May, 2016b) and functional neuroimaging can also be used to 
assess migraine experimental correlates. For example, in the 1940s, Leao first described the 
bioelectrical phenomenon of cortical spreading depression (CSD) (Leao, 1947; Hadjikhani et al., 
2001). Using blood oxygenation level-dependent (BOLD) MRI signal techniques, Hadjikhani et al., 
provided data to support the hypothesis that an electrophysiological event such as CSD generates 
the aura in human visual cortex which was challenging to test before the advent of functional 
neuroimaging (Hadjikhani et al., 2001) (See Page 20). 
 
Functional neuroimaging techniques are indirect measures of neuronal activations. They work 
broadly on the principle that increased neuronal activity would require nutrients and the 
accompanying ‘functional hyperaemia’ would service this purpose. The concept of functional 
hyperaemia was first advanced by Roy and Sherrington (Roy and Sherrington, 1890) who 
demonstrated using animal models, that to meet the nutritional demands of the brain tissue 
secondary to brain activity, there is an increase in cerebral blood flow.  This phenomenon is broadly 
known as ‘neuro-vascular coupling’ (Attwell et al., 2010). Commonly used functional imaging 
techniques include Positron Emission Tomography (PET) and fMRI (functional magnetic resonance 
imaging). Currently no reliable biomarker exists to predict or diagnose migraine attacks. 
Development of functional imaging techniques may one day serve as a diagnostic and predictive 
tool. It may also serve to assess treatment responses to therapeutic agents, by observing their 
effects on the brain activations or alterations in regional cerebral blood flow.  
 
Choosing the right functional imaging modality for a study depends on certain factors that need to 
be considered and also how the chosen imaging modality will address these factors. For example, 
PET imaging and whole brain fMRI modalities are associated with poor spatial resolution when it 
comes to assessing the brainstem (Schulte and May, 2016a). The cerebral blood flow images 
extracted from PET and ASL are similar in qualitative aspects but ASL is superior in spatial resolution. 
With improvements in ASL techniques, even better temporal and spatial resolutions can be expected 







Not all centres are equipped with the technology or the technical staff with expertise to carry out 
functional imaging during spontaneous migraine attacks. Capturing spontaneous migraine attacks 
using functional imaging requires multi-disciplinary resources and the unpredictability of migraine 
attacks adds to the complexity. Using a provoked migraine model mitigates some of these logistical 
issues (Iversen et al., 1989). One could argue whether the spontaneous and chemically triggered 
migraines attacks are one and the same. The argument can be considered at three levels, namely, 
clinical, radiological and molecular. Clinically, triggered patients would develop the symptoms 
required to make a diagnosis of migraine using the International Classification of Headache 
Disorders (ICHD)-3beta criteria (Headache Classification Committee of the International Headache, 
2013). Hence, it would not be possible to tell the difference between a spontaneous migraine and a 
triggered migraine clinically unless one is given the triggering history. However, it must be noted 
that in most provocation studies, for ethical reasons, the migraine headache is treated and not 
allowed to sustain at peak intensity for long periods of time, with abortive treatment so the total 
duration of the attacks is truncated (Afridi et al., 2004b). At a radiological, level, once again, the 
areas activated in spontaneous and triggered migraine appear to be broadly similar (Weiller et al., 
1995; Afridi et al., 2005b; Afridi et al., 2005c; Maniyar et al., 2014a). Now what may be most useful 
in the future to differentiate or connect together, triggered and spontaneous migraine would be to 
understand what happens at a molecular level.  
 
Human models (Thomsen and Olesen, 2001)  have shown evidence of the involvement of nitric oxide 
(NO) acting via cyclic guanosine monophosphate (cGMP) pathways in generating migraine (Stepien 
and Chalimoniuk, 1998). In the NTG human migraine provocation model, it is thought that NTG gets 
converted to nitric oxide in the body and this sets off a cascade of changes responsible for the 
generation of migraine (Olesen et al., 2009). Other provocation models using calcitonin gene-related 
peptide (CGRP) (Lassen et al., 2002), pituitary adenylate cyclase activating polypeptide-38 (PACAP38) 
(Schytz et al., 2009), sildenafil (Kruuse et al., 2003), histamine (Lassen et al., 1995), dipyridamole 
(Kruuse et al., 2006), vasoactive intestinal peptide (VIP) (Rahmann et al., 2008), prostaglandin I2 
(PGI2)(Wienecke et al., 2009) have all been used in various studies, provoking attacks varying from 0-
83% of the subjects enrolled in the studies (Schytz et al., 2010). No study has assessed the migraine 
postdrome in a human migraine provocation model using NTG as the triggering agent and ASL MRI 







1.5 Arterial spin-labeled (ASL) perfusion MRI 
Tissues in the body have varying nutritional and oxygen demands. The demands are met by the 
delivery of the oxygen and nutritional needs by blood and this process is called perfusion. An 
investigation of perfusion due to various physiological states or pathological states can be utilized to 
understand the processes involved, using perfusion based imaging techniques. The most widely used 
perfusion based imaging technique until recently has been PET (Positron Emission Tomography) 
 scanning. However, there are several drawbacks in using PET scanning. It is an expensive technique 
and many hospitals do not have the financial resources to acquire and maintain the infrastructure 
needed for PET scans. The amount of radiation exposure is substantial with an estimated subject 
dose of 25 mSv (millisievert) per whole body 18F-FDG PET/CT examination, independent of clinical 
protocol (Brix et al., 2005). There is also the associated cancer risk with repeat PET imaging that 
limits its widespread use and repeatability (Wen et al., 2013). Arterial Spin-labeled (ASL) perfusion 
MRI is a fMRI technique where the subjects arterial blood is used as an endogenous marker for 
perfusion imaging by magnetically labeling blood water. It is analogous to PET cerebral blood flow 
measurements which use radio decay rate of 15O and the subsequent detection of gamma rays to 
deduce brain activations. However, in ASL MRI, the modified decay rate of longitudinal 
magnetisation from T1 relaxation, induced by the magnetically labelled arterial water is used to 
determine regional CBF (Detre et al., 2012). As it does not involve the use of radioactive tracers, 
radiation related adverse effects and limitations do not apply here.  
 




Substantial radiation risk 
Extensive Infrastructure requirements 
Associated cancer risk  
Limitations in repeatability 
Not suitable for quantitative assessments 
Use of contrast agents that may require hepatic or 
renal metabolism 
 








1.5.1 Core Concepts of ASL MRI 
 
ASL utilizes the principle that the longitudinal magnetization of arterial blood water can be 
manipulated, by which, it will differ from the static tissue magnetization. Using the difference in 
magnetization between labelled and non-labelled images, a subtractive comparison can be made.  
The difference between the image intensity in each voxel is converted to CBF in physiological units in 
ml/g/min (Detre et al., 2009) using a suitable mathematical model. The technique has been 
validated in humans using H215O PET (Ye et al., 2000). 
 
1.5.2 ASL Methods 
 
There are several labeling approaches that can be used for ASL (Alsop et al., 2015; Haller et al., 




Here, a short adiabatic inversion pulse is used to label the arterial blood and the labeling pulses are 
usually located inferior to the brain. The labeling pulses are usually in the region of 10 msec and they 
are meant to invert the blood water instantaneously. Once labeling is done, a sufficient post labeling 
delay period is necessary. This period is also called the inflow time. This is the period where the 
instantaneously inverted blood water moves into the brain and loses its ‘magnetic’ label gradually 
through longitudinal T1 relaxation. Due to this property, the signal to noise ratio (SNR) is intrinsically 
lower than that of pseudocontinuous ASL (PCASL). 
 
Pseudocontinuous ASL (PCASL) 
 
Unlike the comparatively short pulse duration of approximately 10 msec in pulsed ASL, in PCASL, the 
labelling period is made up of multiple very short trains of pulses, each lasting approximately 1 
msec, for a total duration of 1.5-4 seconds. With this train of short pulses, the labelled blood is 
inverted in more or less a steady state manner (Haller et al., 2016). If phase shifts of 180 are made 
on each second pulse, we are in the position to acquire non-labelled control images. The difference 
between labelled and control images can be converted to CBF in physiological units. The advantage 
of PCASL over PASL is that it offers better signal to noise ratio (SNR).  This new ASL method was 








Figure 2. ASL labeling schemes A. PASL- Inversion slab places proximal to imaging volume to label 
blood in the arterial feeding vessels supplying the brain. The pulse is short (approximately 10 
msec) and the blood is inverted simultaneously. B. In PCASL, the inflowing arterial blood is 
continuously inverted as it flows through the labelling plane by means of a process known as flow 
induced adiabatic inversion. The PCASL labelling pulse train is typically applied for a period of 1-2 
seconds. For permissions to use figure, see page 142. 
 
1.5.3 Using PCASL over other ASL techniques in migraine research 
 
PCASL has higher SNR when compared to PASL and hence it is better suited for migraine studies to 
analyse regions of the brain undergoing alterations in cerebral blood flow during various phases of a 
migraine attack. 
 
1.5.4 Post-label delay time 
 
An important aspect to grasp when understanding ASL is the concept of post-label delay time. There 
should be a sufficient post labelling time following the labelling pulse to allow for the labelled blood 






time is set longer than the longest period of transit from the tagging plane and the volume images, 
then the ASL signal becomes impervious to the alterations in the arterial blood water arrival time. 






















2 OUTLINES OF STUDIES AND AIMS  
2.1 The migraine postdrome clinical audit  
2.1.1 Introduction 
Studies have shown that 68-81% of migraineurs have postdrome symptoms (Kelman, 2006; Giffin et 
al., 2016). Previous studies into the postdrome had several methodological flaws. For example, they 
were limited by retrospective data collection, absence of diaries, scarcity of patients and 
heterogeneous classification (Quintela et al., 2006). We performed a clinical audit to gauge the 
impact of the migraine postdrome within our clinical cohort. It is worth noting that a prospective 
diary study into the postdrome (Giffin et al., 2016) addressing all the methodological flaws and aided 
by an electronic diary study, was published only after this clinical audit was underway. Permission 
for the audit was granted by the audit department at King’s College Hospital, London. All data were 
retrieved from clinic records dated from August 2014 to August 2016 following approval by the audit 
department. Clinic records of 100 patients under the care of Professor Peter J. Goadsby at King’s 
College Hospital, London, were examined to obtain data against an audit collection tool. Migraine 
diagnosis was made using ICHD-3 (beta) criteria (Headache Classification Committee of the 
International Headache, 2013).  
For the purpose of this audit, the migraine postdrome was defined as the time between headache 
resolution and feeling completely back to normal. Headache resolution was defined as cessation of 
troublesome throbbing headache (Giffin et al., 2016) 
 
 
Figure 3. Broad Classification of Postdrome symptoms (Bose and Goadsby, 2016) 
 
2.1.2 Background behind the audit  
Migraine is the 6th most disabling disorder worldwide (2017) and affecting an estimated 15% of the 
UK adult population (Steiner et al., 2003). In 2003, it was estimated that in the United Kingdom, 
approximately 25 million work days were lost due to migraine each year (Steiner et al., 2003). This 
would impact the patients’ health, social and financial commitments and have a negative impact on 
the economy due to loss of productivity. 






different migraine phases, remains the postdrome (Bose and Goadsby, 2016). The four main phases 
of a migraine attack: premonitory, aura, headache, and postdrome, are well described in textbooks 
(Lance et al., 2005) whereas the postdrome is not yet defined in the International Classification of 
Headache Disorders (Headache Classification Committee of the International Headache, 2013). 
Although the symptoms here may have classically been thought of as less dramatic than the pain of 
the headache phase, the symptoms are no less disabling. In a study involving 34 patients, postdrome 
symptoms were reported to impact the ability to work, to affect family interactions and social life, 
and to cause cognitive impairment (Ng-Mak et al., 2011). A larger study involving 827 patients 
reported that 68% of patients experienced postdrome symptoms, with an average duration of 25.2 
hours (Kelman, 2006). In a prospective electronic diary study, among 120 evaluable patients, 97 
(81%) reported at least one non-headache symptom in the postdrome thereby contributing to the 
distress and disability of the subjects (Giffin et al., 2016). Blau described 255 symptoms in the 
postdrome for a cohort of 40 patients with an average duration of 18 hours (Blau, 1991). The most 
common symptoms reported in this study included tiredness, head soreness, cognitive difficulties, 
hangover, mood changes, and dizziness. However, it was difficult to distinguish between certain 
symptoms for example, a subdued mood, depressed mood, bad mood, and introverted mood. To 
rectify this, Quintela and colleagues (Quintela et al., 2006) assigned postdrome symptoms into four 
groups: neuropsychiatric, sensory, gastrointestinal (digestive as per the authors), and general 
symptoms which is a very useful way to classify postdrome symptoms. 
 
Hence, the postdrome phase of a migraine attack can prolong disability for patients. It is essential to 
fill this knowledge gap regarding the migraine postdrome and get this phase defined and included in 
the International Classification of Headache Disorders (Headache Classification Committee of the 
International Headache, 2013). Though research studies have looked into the extent of postdrome 
previously (Quintela et al., 2006; Giffin et al., 2016), the purpose of carrying out a clinical audit was 
to evaluate the extent of the problem within our clinical patients and to see if the problem was as 







2.1.3 Migraine postdrome clinical audit aims 
 
The aims of the audit were to explore using a clinical audit: The migraine postdrome as it presents 
and to categorize the disabling symptoms patients report. 
 
Following the identification of the group of patients who experienced postdrome, the next step was 
to ask the question: what variables affected the presence of the postdrome phase.  
 
The variables considered were: attack duration (in hours), migraine type, medication overuse*, age 
(in years), gender, co-morbidities, lateralisation of pain, CAS (Cranial Autonomic Symptoms), 
photophobia, phonophobia, osmophobia, motion sensitivity.  
 
*The definition for medication overuse was dependent upon the pharmacological class of 
medication. The definitions used for this project were based on the guidelines of the International 
Headache Society (Headache Classification Committee of the International Headache, 2013). The 
following was taken as medication overuse: Triptans, opioids: 10 days per month for a period of 3 
months and over the counter (OTC) medications like paracetamol and NSAIDs: 15 days per month of 







2.2 THE MIGRAINE POSTDROME ARTERIAL SPIN LABELED (ASL) MRI IMAGING STUDY (POSTD)  
The study was carried out in accordance with the World Medical Association Declaration of Helsinki, 
1964 (Rickham, 1964), the Research Governance Framework for Health and Social Care (2nd edition, 
2005), the Data Protection Act (1998) and the principles of Good Clinical Practice (GCP). Study 
approval was granted by the Health Research Authority – Camden & King’s Cross Research Ethics 
Committee (REC) Ethics (Ref: 14/LO/2241 UKCRN ID: 18439) and the King’s College Hospital 
Research Office (Hospital study code - KCH15-027). The principal aim of this study was to investigate 
alterations in cerebral blood flow during the postdromal stage of a migraine attack using a NTG 
triggered human migraine model. 
 
2.2.1 Primary hypothesis:  
The primary hypothesis behind this study was that the brain areas identified as having increased 
cerebral blood flow (CBF) in the premonitory phase of migraine, such as the hypothalamic region, 
and the attack phase, such as the dorsolateral pons based on previous studies (Maniyar et al., 
2014a), continue to be active in the postdrome phase. We suspected this based on the similar 
nature of symptoms reported in the premonitory phase and the postdrome (Giffin et al., 2003; 
Maniyar et al., 2014a; Giffin et al., 2016). 
 
2.2.2 Aims of POSTD Imaging study  
2.2.2.1 Primary aim 
 
To study the alterations in cerebral blood flow during the postdrome phase of a migraine attack 
using Arterial spin labelled (ASL) MRI, relative to the baseline and premonitory phases. 
2.2.2.2 Secondary aims 
 
a. To study changes in attention, fatigue and sleepiness during the postdrome phase compared to 
baseline. 
b. Clinical phenotyping of the subjects’ symptoms and clinical features during different phases of the 






















3 PREVIOUS ASL STUDIES IN MIGRAINE 
ASL MRI techniques have been used extensively to quantify several pain states and has been 
validated as a reliable and reproducible technique (Howard et al., 2011; Howard et al., 2012; 
Hodkinson et al., 2015a). The use of ASL in migraine studies is relatively new. Kato and colleagues 
used ASL MRI to study a single patient during 3 stages: One hour into a migraine attack, 30 minutes 
following treatment with 10mg of rizatriptan and finally, once the subject was attack free. The 
normalized images attained during the migraine headache stage, showed significant relative 
hypoperfusion on the bilateral medial thalamic regions that included the hypothalamus, and there 
was significant relative hyperperfusion in the frontal cortex when these images were compared to 
the pain free period. When images were acquired within 30 minutes of treatment with rizatriptan, 
they showed a recovered significant relative perfusion in the hypothalamus when the images were 
compared to the migraine headache scans (Kato et al., 2010). 
 
Figure 4. Normalized ASL images during migraine attack show significant relative hypoperfusion in 
bilateral thalamic areas including hypothalamus, posterior cingulate, and cerebellum, and 
significant relative hyperperfusion in the frontal convexity as compared to the migraine-free state. 
b Normalized ASL images acquired 30 min after rizatriptan administration demonstrated 
recovered significant relative perfusion in the hypothalamus and its surrounding areas as 
compared to during migraine attack. a, b Two-tail view. Colour bar is Z-score (SD) (For Permission 







Pollock and colleagues published a case series involving 11 subjects, showing regional cortical 
hyperperfusion during migraine attacks. They concluded that ASL perfusion studies have significant 
potential in evaluating symptomatic migraines in the future (Pollock et al., 2008). 
 
ASL techniques have also been used to show an altered pattern of regional cerebral blood flow 
involving the primary somatosensory cortex in the interictal phase of migraineurs when compared to 
age and sex matched healthy controls (Hodkinson et al., 2015b). Whether these changes suggest 
adaptation or maladaptation to multiple migraine attacks, remain unclear. 
 
These studies show that ASL is a versatile tool to investigate perfusion changes in migraine with an 
unprecedented level of spatial detail. They also offer potential to assess therapeutic response in 





















4 METHODS  
 
4.1 Methods - Migraine postdrome clinical audit 
 
The clinic records of 100 random patients under the care of a UK headache tertiary care centre, 
King’s College Hospital, London were examined to obtain data against an audit collection tool. 
Permission for clinical audit was granted by the hospital clinical audit department. All the records 
obtained were for patients under the care of Professor Peter Goadsby. Migraine diagnosis was made 
using ICHD-3(beta) criteria (Headache Classification Committee of the International Headache, 
2013). Predetermined data based on previous studies (Blau, 1991; Kelman, 2006) was extracted and 
analysed. This included symptoms in the postdrome, such as neuropsychiatric, gastrointestinal, 
sensory and general systemic (Quintela et al., 2006; Kelman, 2007; Bose and Goadsby, 2016). The 
presence of co-morbidities including depression, anxiety, hypertension and fibromyalgia, and 
overuse with medications such as simple analgesics, triptans, opioids, and cannabinoids were 
extracted (See Table 2, Figure 5,6 and 7 for audit data extraction tools used). The data regarding the 
basic demographics of the cohort was extracted using Microsoft Excel (Microsoft Office, 2016). 
Statistical analysis of the whole data set (both postdrome and non-postdrome group) was assessed 










AUDIT EXTRACTION TOOL 
Age (years) 
Gender  
Headache duration (hours) (continuous also set) 
Migraine Type  
Lateralization of Pain 
Site of Attack  
Severity of Head Pain (out of 10)  






General Systemic Symptoms 
Cranial Autonomic Symptoms (CAS) 
Co-morbidities 
Medication overuse 





















Figure 6. Extraction tool used to identify postdrome presence and the symptoms experienced 







Figure 7. Other variables accounted for during information extraction 
 
4.1.1 Statistical analysis 
Data was then exported (IBM SPSS Statistical software package, Version 23 for Mac) for analysis 
using the most appropriate statistical tests for the extracted data.  
The statistical analysis was performed to assess the variables and their association with the presence 
of postdrome). The tests used were: 
Independent samples t-test (for continuous variables) or Chi Square test (for categorical variables). 
The Fisher’s Exact Test was reported instead of the Chi-square Tests when one or more cells had 
expected cell counts of less than five. 
The Kolmogorov-Smirnov test was also utilized and A two-sided significance level of 5% was applied 
to all hypothesis tests. The Kolmogorov-Smirnov test (KS-test) tries to determine if two datasets 







4.2 Methods- POSTD Imaging study 
 
4.2.1 Study population  
The target population for the study was 60 subjects aged between 18 and 50 years of age with a 
diagnosis of migraine with or without aura.   
 
4.2.2 Recruitment sites 
Relevant permission was obtained to recruit subjects through King’s College Hospital, Denmark Hill, 
Guy’s Hospital, Royal London Hospital, Basildon Hospital, St George’s Hospital, Croydon University 
Hospital, Frimley Park Hospital, Kingston Hospital and St Peter’s Hospital. Subjects were also 
recruited through The Migraine Trust and Migraine Action websites. An advertisement was also 
placed in a local newspaper (Metro). King’s College London sends out a research bulletin to staff and 
students on a fortnightly basis, which also served as a recruitment route. Subjects received a patient 
information sheet (PIS) and gave permission to be contacted by me, after having adequate time to 
consider participation. Once they agreed to participate, they were given a headache diary. Subjects 
who contacted after reading the information leaflet, underwent a telephone screening to review if 
they met the inclusion criteria (see Page 147). Those who were eligible, were invited for a NTG 
triggering visit. Once they attended the first visit, informed consent was taken and the subject 








Figure 8. Recruitment flowchart. In total, 235 subjects contacted the study team. Following telephone 
screening, 81 subjects were found to be eligible and were invited to attend a screening visit. 46 subjects 
attended the screening visit. 16 subjects completed all study visits. 
 
4.2.3 Inclusion and exclusion criteria for the study  
Subjects needed to meet all the inclusion criteria to be eligible for enrolment into the study. Key 
inclusion criteria were: subjects with a history of migraine with or without aura and between the age 








4.2.4 Lifestyle guidelines whilst enrolled in the study 
 
The presence of lifestyle factors that could potentially affect cerebral blood flow or functional 
network connectivity were assessed. Subjects were asked to abstain from caffeine-containing 
products for 12 hours prior to each visit as this could potentially affect cerebral blood flow (Field et 
al., 2003). Similarly, subjects were asked to abstain from taking NSAIDs (non-steroidal anti-
inflammatory drugs) or paracetamol for 12 hours prior to each visit. They were also asked not to 
smoke more than five cigarettes per day or consume more than six cups of caffeinated drinks per 
day for the duration of the study. They were asked to abstain from the use of tobacco or nicotine 
containing products for four hours prior to admission until discharge for each visit and were asked to 
abstain from taking alcohol for 24 hours prior to each visit. Alcohol and nicotine are known to alter 
the resting state Functional Network Connectivity in the brain (Kelman, 2004; Vergara et al., 2016, 
2017). Subjects were asked to maintain a normal sleep routine for the duration of the study.  
 
4.2.5 Study endpoint 
Alterations in rCBF using pCASL with 3D fast spin echo (FSE) readout across baseline, premonitory, 
migraine headache and postdrome phase. 
 
4.2.6 Study design  
The study design involved three visits to the Clinical Research Facility, King’s College Hospital, 







Figure 9. Visit 1 Flow chart 
 
Visit 1 (screening visit)  comprised familiarization, phenotyping, physical examination, ECG 
examination and a test infusion of NTG to assess and confirm how many of the recruited subjects 
developed premonitory symptoms, migraine headache and postdromal symptoms in response to 
NTG triggering (via oral questioning for establishing stage of attack and onset of postdrome), as 
migraine headache development in response to NTG is not universal to all migraineurs (Afridi et al., 
2004b). Subjects who did not trigger in response to NTG, or who did not display symptomatology 
compatible with the study arm timelines were excluded from further visits at this point.  
Subjects were instructed to consume only a light breakfast prior to each study visit. The subjects 
were provided meals at the end of completion of each study visit. During each visit following the 
triggering infusion, subjects were kept nil by mouth but were given intravenous 5% dextrose-normal 
saline infusion to maintain hydration and to prevent feelings of hunger. Additionally, intravenous 
fluids are part of standard care for acute migraine. Preventing oral food intake during each study 
visit would minimize vomiting and subsequent complications which maybe present once a migraine 
is triggered. Food and oral intake (Field et al., 2003; Frank et al., 2012) have been shown to have an 
effect on cerebral blood flow, and this would make it difficult to interpret whether changes seen on 
imaging are actually related to migraine processes itself.  






premonitory symptoms, migraine headache and postdrome following treatment for each 
successfully triggered subject, so that these timelines could be used to plan scanning times for 
further study visits. Previous studies had shown that this timeline for patients is reproducible on 
separate occasions using NTG triggering (Afridi et al., 2004b). Subject symptoms during the 
postdromal phase were meticulously analysed. Their current treatments and their responses to 
various treatments were reviewed and formed the basis for the decision with regards to which 
treatment to use to treat the NTG induced migraine attack (i.e. 6mg subcutaneous sumatriptan or 1-
gram intravenous aspirin). 
Subjects were given intravenous aspirin or subcutaneous sumatriptan to treat the migraine 
headache post triggering. Once the headache was treated, the subjects were assessed for the 
presence of postdromal symptoms.  
During Visit 1, subjects were also offered the chance to familiarise themselves with the MRI scanner 
environment by having the screening visit in the vicinity and by having the opportunity to lie in a 
mock scanner, if desired. However, none of the subjects requested access to the mock scanner 
during the first visit. 
We attempted to characterize the neuropsychiatric symptoms encountered during the postdromal 
phase of a migraine attack. During subsequent visits following the screening visit, subjects 
underwent validated questionnaires to assess sleepiness (Kaida et al., 2006), attention (Robertson et 
al., 1997; Dillard et al., 2014) and fatigue (Fisk and Doble, 2002) during baseline stage of a non-
triggered (placebo) visit or during the postdrome phase of a NTG triggered subsequent visit. A one-
off Migraine Impact on Daily Activities Scale (MIDAS) was also conducted at baseline prior to any 
triggering, at Visit 1.   
The validated questionnaires to compare the sleepiness, attention and fatigue for the baseline 
versus the postdrome phase were administered on two different visits to minimize any practice 
(Goldberg et al., 2015) and order (Cole et al., 2016) effects. For the same reason, the Sustained 
Attention Response Task (SART) (Manly et al., 2002) was chosen, a computer based validated 
questionnaire to assess attention span, that shows multiple random numbers and asked the subject 
to click the space bar for every random number that flashes except for the number ‘3,’ as a test to 
measure attention span. The randomness of the numbers that flash on the computer screen, meant 
that it avoided any order or practice effect.  
The questionnaires took about 20 minutes in total, to complete and were administered only once at 
each subsequent study visit after Visit 1 and were administered either at the baseline phase of a 
non-triggered visit or postdrome phase of a triggered visit.  






symptom free prior to attending for the next visit and to ensure that they were still willing to attend 
for the visit and partake in the study. They were warned to monitor closely migraine headache onset 
prior to attending for each study visit and were instructed to reschedule the study visit if they had a 
headache or active menstruation.  
Participants assigned to the study underwent two further visits, a triggered and a non-triggered visit, 
in addition to Visit 1, but the order, triggered vs non-triggered visit, at which they attended these 
visits were randomised. Randomisation was determined via a computerised code using Microsoft 
Excel, after formal written consent was taken. 
One of these visits (triggered visit) involved triggering migraine with an infusion of NTG and treating 
with sumatriptan 6mg subcutaneous injection or 1 gram intravenous aspirin, when there was 
moderate to severe pain on a verbal rating scale (score of 2-3)(Skovlund and Flaten, 1995), and the 
other visit (non-triggered) involved a placebo infusion (normal saline) and subcutaneous sumatriptan 
6mg injection or intravenous 1 gram aspirin, given at the same treatment time based on information 
derived from the first visit (screening visit). All the drug agents used for infusion in the study 
(NTG/placebo) were administered intravenously through a cannula placed on the dorsum of the 
hand or antecubital fossa.  
 







Figure 11. Sequence of events at Visit 2/3- Non-triggered visit 
 
Before and after each scan series, pain intensity was assessed using a verbal rating scale. This is the 
suggested scale from the International Headache Society, using scores of 0-3 to score pain, with 0 
being pain free and 3 being severe pain (Skovlund and Flaten, 1995). The purpose of a non-triggered 
visit was to control for any potential impact on brain imaging from diurnal alterations in rCBF 
(Hodkinson et al., 2014), by imaging the same subjects throughout the day in the absence of 
headache. Hodkinson et al, had previously shown that the homeostasis of the hypothalamic-
pituitary-adrenal axis has a role in modulating functional integrity of the default mode network 
(DMN) and hence when using functional imaging, to assess disease processes, it is important to 
factor in changes related to circadian rhythm when assessing alterations in cerebral blood flow 
(Hodkinson et al., 2014). The purpose of administering subcutaneous sumatriptan or intravenous 
aspirin during the non-triggered scanning visit was to control for any effects sumatriptan or aspirin 
may have on cerebral blood flow which may affect end analysis and to ensure that the alterations in 
regional cerebral blood flow seen in the postdrome phase of a triggered visit is not a drug effect. 
Imaging was performed at both of these visits (triggered and non-triggered).  
During Visit 2 and 3, patients, were infused with either NTG or normal saline, depending whether it 
was a triggered or non-triggered visit respectively, and underwent four scans per visit; a baseline 
scan, ‘premonitory’ scan, ‘migraine headache’ scan and a ‘postdrome’ scan. At each scanning point, 






minimum of 2-week interval from each other and from Visit 1 to allow a pain free and recovery 
period prior to re-triggering. Subjects had to be headache free for 24 hours prior to each study visit. 
This was assessed through a detailed headache diary that each subject was asked to keep.  
Before the infusion, subjects were assessed for headache symptoms via oral questioning to ensure 
symptom freedom. Following NTG/placebo infusion, the onset of headache symptoms was assessed 
at periodic intervals initially every 5 minutes until the end of infusion in twenty minutes and then 
less frequently, every 10–15 minutes and finally during the postdrome. Further detailed questioning 
with regards to typical premonitory symptoms, yawning, mood changes and frequency of 
micturition, occurred at intervals to establish what stage of an attack subjects were in. Any changes 
in symptoms from baseline was considered positive. During moderate to severe migraine, as 
determined the verbal rating scale, subjects were treated with sumatriptan 6 mg subcutaneous 
injection or 1-gram intravenous aspirin. If the subject received a placebo infusion in the non-
triggered visit, they still received sumatriptan 6mg subcutaneous or 1-gram intravenous aspirin 
injection at the same time of moderate to severe migraine headache onset derived from Visit 1 (NTG 
triggered visit). The subject was blind to which agent (placebo or NTG) they are receiving as the 
infusion during visit 2 and 3. This was to ensure unbiased analysis of the study data and to avoid a 
placebo response. 
4.2.7 Sample size  
 
The target completed sample size for this study was determined to be for 16 patients to go through 
to study completion (to go through from visits 2-3, after having been identified as suitable from Visit 
1. Based on normative CBF data sets collected in many ASL based studies (Howard et al., 2011), we 
have been able to ascertain that with a standard deviation of 10% (from a grey matter mean of 50 
ml/blood/100gm tissue/minute), 16 subjects are needed to observe a change of 5 ml blood/100gm 
tissue/min (effect size 0.8 using G-power).  ASL based publications from this institution confirm 
these numbers (Howard et al., 2011; Howard et al., 2012; Hodkinson et al., 2013; Hodkinson et al., 







4.2.8 Procedures involved during each study visit 
 
4.2.8.1 Visit 1 (Screening, Phenotyping and Familiarisation Visit) 
 
During this visit, a very thorough medical history was taken with characterisation of migraine, 
premonitory and postdrome symptoms. The medication history was noted to ensure there was no 
contraindication to any of the study drugs used. A pregnancy test was performed on all female 
subjects of childbearing age to exclude any risk of imaging and any risk from study drugs, whilst they 
were pregnant. Randomisation of study visits 2 and 3 (triggered and non-triggered visits) was also 
performed at this stage. 
 
4.2.8.2 Visits 2-3 - Triggered and Non-triggered visits  
Each subject was contacted on the day prior to the study visit to verify attendance and to assess for 
the presence of any ongoing or paroxysmal pain or the onset of any premonitory symptoms prior to 
the study visit. A pregnancy test was performed on all female subjects of childbearing age to exclude 
any risk of imaging and any risk from study drugs whilst they were pregnant, for each study visit. (For 
Diagram see Page 51).   
ASL measurements were conducted during each study visit and total measurement sequences lasted 
approximately 30-45 minutes per individual scanning session.  
 
4.2.8.3 Study treatments  
During the visits, NTG or a placebo (normal saline) infusion was administered through a syringe 
driver, aspirin 1 gram given as an IV bolus or 6mg sumatriptan administered subcutaneously by a 
trained medical professional. 
In between scanning sessions, subjects were monitored for the occurrence of a non-specific NTG 
triggered featureless headache, premonitory symptoms, migraine headache and postdromal 
symptoms. No questioning or pain scoring were performed during scanning to prevent any 
interference with the imaging sequences and to avoid task related changes in rCBF during imaging. 
4.2.8.4 Prior to discharge  
Subjects’ observations and pain scores were reassessed to ensure safety for discharge and rescue 
medication advice were given. Nausea and/or vomiting was also controlled through administration 
of appropriate anti-emetic therapy if needed. They were advised to be accompanied by someone 







4.2.9 Assessments  
All of the patient questionnaires, apart from the MIDAS which was completed once only during visit 
1, were completed at one stage of an attack at each study visit in each study arm after visit 1 
(screening visit). The stage at which they were performed was determined by randomisation and 
occurred at baseline during the non-triggered placebo visit and during the postdrome in the 
triggered visit.   
4.2.9.1 Migraine related disability  
 
The MIDAS (Migraine Disability Assessment Score) was conducted at baseline during visit 1 just once 
to determine the functional impact of the disorder on the subjects’ lives. The Migraine Disability 
Assessment (MIDAS) score is used to quantify headache-related disability. This is a validated scale 
for assessment of migraine impact on the activities of daily living. The reliability and internal 
consistency of the MIDAS scores are high, as tested in a population-based sample of headache 
sufferers (Stewart et al., 1999). 
4.2.9.2 Attention  
 
Attention was tested using a computer-based programme, SART. Permission from the authors was 
granted to use this test (Robertson et al., 1997). This is a validated measure of attention and 
concentration, used widely in psychology assessments.  
4.2.9.3 Sleepiness and alertness  
 
Sleepiness and alertness was assessed with the validated Karolinska Sleepiness Scale (KSS) 
(Akerstedt et al., 2014). Permission from the author was kindly granted to use this test. 
4.2.9.4 Fatigue  
 
Fatigue was assessed using a daily fatigue impact scale (D-FIS) (Fisk and Doble, 2002). This is a 
validated, widely used questionnaire to semi-quantitatively assess fatigue.  
4.2.9.5 Perceived pain intensity  
 
Estimates of perceived pain intensity was acquired using a previously used and validated Verbal 
rating scale, as per the International Headache Society guidelines for drug treatments (Skovlund and 
Flaten, 1995). Perceived pain intensity was measured during monitoring periods throughout each 








4.2.9.6 Premonitory, migraine headache and postdromal questionnaire  
 
Oral questioning regarding premonitory, migraine headache and postdromal symptoms occurred 
throughout each study visit to help ascertain which phase of migraine the subject was experiencing. 
These included questioning about typical premonitory and postdromal symptoms such as cravings, 
photophobia, phonophobia, thirst, frequency of micturition, yawning, mood changes, fatigue, 
concentration changes and character of headache questions including site, laterality, severity and 
character of pain. Answers involved the subjects’ individual experiences and any change from 
baseline involving 3 or more symptoms was taken as positive. These were asked at 5-10 minutely 
intervals following the initiation of NTG or placebo infusion, for 20 minutes and every 15-20 minutes 
thereafter, to ascertain which stage of an attack subjects were in. The approximate timeline was 
acquired for each subject from visit 1 and from previous studies, there is usually minimal variability 







4.2.10 NTG triggering  
Subjects underwent NTG triggering in the Clinical Research Facility at King’s College Hospital, 
London. The dose for NTG infusion has been established based on previous other studies and was 
set at 0.5mcg (microgram)/kg/minute over 20 minutes, administered through an intravenous syringe 
driver pump (Iversen et al., 1989; Afridi et al., 2004b). No analgesics was prescribed, unless the 
subject reached moderate to severe migraine headache as per the verbal rating scale, at which point 
rescue medication (either 1-gram intravenous aspirin or 6mg subcutaneous sumatriptan) was 
administered. All subjects were treated following the scanning session at the onset of moderate-
severe migraine headache during the second triggered visit. 
4.2.11 MRI  
MRI examinations were conducted by qualified radiographers within the scanning facility at the 
Clinical Research Facility, King’s College Hospital, London and all imaging data were collected using a 
3T whole-body MRI scanner with capability for parallel image acquisition. MRI measurements were 
performed at visit 2 and 3. No MRI scan was performed at visit 1. All imaging took place between 
0900-1700, to account for standardization of scanning time of day and diurnal variability (Hodkinson 
et al., 2014). Total time of imaging per visit did not exceed 2.5 hours. The 3 T whole-body MRI 
scanner (GE MR750) was fitted with a receive-only 8-channel, phased-array head coil. For image 
registration purposes, a high resolution T2-weighted Fast Spin Echo (FSE) image was acquired. 
Perfusion measurements were made using a pseudocontinuous ASL (pCASL) sequence (Dai et al., 
2008). Labelling was performed using a train of Hanning RF pulses; 500 μs duration, peak-to-peak 
gap 1500 μs, and a total labelling duration of 1.5 s. After a post-labelling delay of 1.5 s, the image 
was acquired with a 3D FSE inter-leaved spiral readout (8 shots, TE/TR = 32/5500 ms, ETL = 64, 3 
tag–control pairs). Pre-saturation of the image volume, followed by selective inversion pulses for 
background suppression, was also acquired in order to minimise the static signal. A proton density 
reference images was used for the computation of the CBF maps in physiological units (ml blood per 
100 g of tissue per min). Each ASL took 6 minutes to acquire.  Two were collected in each scanning 
period to increase SNR.  Participants were instructed to lie still with their eyes open.  
Because of the genuine three-dimensional encoding and readout of this multi-shot technique, and 
the refocusing of magnetic susceptibility induced signal distortions, the maps of CBF obtainable with 
this technique are of good image quality and exquisite spatial resolution (3.6 x 3.6 x 3mm).  
Quantification of rCBF using pCASL was repeated multiple times within a session for determination 
of the temporal stability of CBF, and to gain an insight into the temporal variation of the 







4.2.12 Withdrawal  
If a subject withdrew from the study and also withdrew consent for disclosure of future information, 
no further evaluations were performed, and no additional data were collected. None of the subjects 
enrolled in the study withdrew consent. 
4.2.13 Research Related Injury  
A medically important research related injury is any untoward medical occurrence that: Results in 
death or is life-threatening (immediate risk of death or results in persistent or significant 
disability/incapacity. No subject involved in the study sustained a medically important research 
related injury. 
4.2.14 Medication handling  
All medication was cross checked for name, dose, batch number and expiry date with a research 
nurse or a medical doctor. All drug administration was checked by two individuals, including the 
drug administrator and a research nurse or a medical doctor. All drug batch numbers and expiry 
dates, as well as drugs administered, times and doses were recorded in the source file.  
After drug administration, and after completion of each study visit, all sharps were disposed of 
safely, and all contaminated needles and syringes, including used sumatriptan cartridges were 







4.2.15 Data analysis 
4.2.15.1 Data pre-processing  
 
All analyses were conducted using analysis toolboxes available in Statistical Parametric Mapping 
(SPM version 12) (http:// www.fil.ion.ucl.ac.uk/spm). Each of the rCBF time-series was normalised 
into a standard reference space (MNI) to allow for comparisons across individuals. Data was also 
spatially smoothed to accommodate for gyral variability across subjects and to improve SNR. 
4.2.15.2 Statistical analysis  
 
4.2.15.2.1 First level  
An average of the two CBF maps (see Page 57)  for each time point (i.e., premonitory, migraine 
headache and postdrome) was computed for each individual.  
4.2.15.2.2 Second Level  
Individual subject data from first level analyses provided inputs to paired t-test analyses. Paired data 
for the following six scan comparisons were done: 
A- Baseline scans of all subjects compared with premonitory scans of all subjects. 
B- Baseline scans of all subjects compared with migraine headache scans of all subjects. 
C- Baseline scans of all subjects compared with postdrome scans of all subjects. 
D- Premonitory scans of all subjects compared with postdrome scans of all subjects. 
E- Migraine headache scans of all subjects compared with postdrome scans of all subjects and 
F- Non-triggered (placebo) visit scan comparison, which is a comparison of all scans done at the time 
onset of migraine headache derived from screening visit, with the scan done at the comparable time 
of postdrome, derived from screening visit following administration of aspirin/sumatriptan to assess 
qualitatively alterations in rCBF related to aspirin/sumatriptan (See Page 52).  
 
Voxel-wise contrasts of parameter estimates were computed, resulting in several whole brain maps 
reflecting the changes in rCBF following triggering and onset of the different migraine phases and 
also following treatment across subjects. After appropriate statistical thresholding (cluster-corrected 
alpha <0.05, derived from an uncorrected voxel p-value of 0.01), the resulting statistical parametric 
maps indicated local changes in rCBF that differ during the premonitory and headache phases of the 
attack, as well as following recovery of headache, in the postdrome phase. For exploratory purposes 
a small volume correction was applied with sphere set at 12mm radius of voxel of interest (VOI) to 






In addition to the voxel-wise, unbiased analysis, rCBF data were extracted from anatomically defined 
ROIs in hypothalamus, midbrain, pons, thalamus, insula and anterior cingulate cortices.  Functional 
imaging data support the role of these regions in the pathophysiology of migraine (Weiller et al., 
1995; Maniyar et al., 2014a; Schulte and May, 2016a). With the exception of the hypothalamus, 
anatomical ROIs in MNI template space were derived from the Harvard-Oxford Cortical and 
Subcortical Atlas (http://www.fmrib.ox.ac.uk/fsl/) and Juelich Histological Atlases (Amunts et al., 
2005). Due to the relatively small size of hypothalamus, ROI extraction was performed manually in 
each subject. Summary measures for each subject in each ROI was used as conventional univariate 
endpoint. A paired t-test was performed for each ROI and comparisons were made between 
premonitory vs postdrome rCBF data.  
4.2.16 Data handling, record keeping, quality control and quality assurance  
During the study conduct, data was reviewed to ensure that the protocol and Good Clinical Practices 























5.1 Results of migraine postdrome clinical audit 
5.1.1 Demographic characteristics 
The age range in this cohort varied from 17 to 77 years (n = 100), with a female preponderance (n = 
85). The mean age was 46 [13]. 
 
5.1.2 Postdrome reported 
A postdrome was reported in 86% of patients with an average duration of 45 hours. The duration of 
postdrome was however only noted in three cases. The majority (72%) of postdrome sufferers 
within our cohort were chronic migraineurs with mostly bilateral headache (46%). Medication 
overuse was present in 44% of patients with 39% reporting postdromal symptoms. Simple analgesics 



























5.1.3 Postdrome Symptoms.  
The most prevalent symptom was tiredness (77%) followed by neuropsychiatric (39%) and 
gastrointestinal (7%) symptoms. The most prevalent gastrointestinal symptom was food craving (4%) 
followed by an aversion to food (2%). Sensory symptoms (2%) such as photophobia and head 
soreness were also reported in the postdrome. Twenty-six percent of the cases who developed 
postdrome symptoms, specifically mentioned in clinic that their symptoms were disabling. However, 
for 74% of patients presenting with postdrome, it was not recorded whether the symptoms were 
disabling or not. A breakdown of the neuropsychiatric symptoms highlights difficulties in 
concentration (31%) as the most common followed by mood changes (26%). 18 patients exhibited 
both concentration trouble and mood changes. 
 





General Systemic  77 
Cranial Autonomic Symptoms (CAS) 0 











5.1.4 Headache Characteristics 
The mean headache duration in this cohort was 57 [13] hours. Continuous headache was reported 
in 51%. Chronic migraine  was diagnosed in 83% (Headache Classification Committee of the 










Migraine Type (%) 
Chronic 83 
Episodic 17 

















5.1.5 Associated features 
Photophobia was bilateral in 86% cases. Phonophobia was bilateral in 75%. Phonophobia was not 
present in 22%. Osmophobia was present in 45%. Motion sensitivity was present in 84%. Various 
cranial autonomic symptoms (CAS) were reported in the headache phase. At least one CAS was 





















Not present 22 
Osmophobia (%) 
Present 45 
Not present 55 
Motion Sensitivity (%) 
Present 84 
Not present 16 













Cranial autonomic symptoms (CAS)(%) 




Facial flushing 15 
Conjunctival injection 11 
Eye redness 12 
Rhinorrhoea 10 
Oedema 7 
Eye watering 6 
Swelling of cheek 1 
Miosis 0 
Mydriasis 0 




Patients having postdromal symptoms had documented evidence of certain co-morbidities like 
depression, hypertension, anxiety and fibromyalgia. Medication overuse was present in 44% of the 













Medication Overuse (%) 
Opioids 13 
Simple Analgesics 29 
Triptans 17 







5.1.7 Statistical analysis 
Based on the basic demographic results and previous literature, it was decided to continue analysis 
on the following variables to determine any association with the presence of a postdrome.  
 
5.1.7.1 Attack Duration 
The headache/attack duration (in hours) in the population followed a normal distribution. The 
Kolmogorov-Smirnov test was not significant at the 5% level and thus an independent samples t-test 
was carried out assuming equal variances. This showed no differences in the headache duration (in 
hours) distribution between the postdrome (n= 86) and non-postdrome (n= 14) group (P = 0.254). 
 
5.1.7.2 Migraine Type (Chronic vs Episodic) 
There was no difference in the presence of a postdrome amongst chronic vs episodic (P=0.702). 
 
5.1.7.3 Medication Overuse  
There was no difference in the presence of a postdrome amongst those with and without 
medication overuse (Pearson Chi-Square, 0.454, df=1, P=0.501). There was also no difference in the 
presence of medication overuse amongst males and females (P= 0.821).  
 
5.1.7.4 Age 
As the age in the entire cohort followed a normal distribution and as the Kolmogorov-Smirnov test 
was not significant at the 5% level, an Independent Samples t-test was carried out assuming equal 
variances. This showed no differences in age distribution between the postdromal (n=86) and non-
postdromal (n=14) group (P=0.935). 
 
5.1.7.5 Gender 









There was no difference in the presence of a postdrome amongst those with hypertension (n=8) and 
those without (n=78) (P=0.182). 
 
5.1.8.2 Fibromyalgia 
There was no difference in the presence of a postdrome amongst those with fibromyalgia (n=4) and 
those without (n=82) (Fisher's exact test, P=0.537).  
 
5.1.8.3 Depression 
There was no difference in the presence of a postdrome amongst those with depression (n=13) and 
those without (n=73) (Fisher's exact test, P=0.537). 
 
5.1.8.4 Anxiety 
There was no difference in the presence of a postdrome amongst those with anxiety (n=6) and those 
without (n=80) (Fisher's exact test, P=1.000). 
 
5.1.8.5 Lateralisation of Pain during headache phase 
There was no difference in the presence of a postdrome amongst those with unilateral, bilateral or 
alternating headache (Fisher's exact test, P=0.198). 
 
5.1.8.6 CAS during headache phase 
There was no difference in the presence of a postdrome amongst those with CAS during migraine 
and those without (Pearson Chi-Square, 0.496, df = 1, P = 0.481).  
 
5.1.8.7 Photophobia during headache phase 
There was no difference in the presence of a postdrome amongst those with unilateral/bilateral/or 
no photophobia during headache phase and those without (Fisher's exact test, P=0.376). 
 
5.1.8.8 Phonophobia during headache phase 
There was no difference in the presence of a postdrome amongst those with phonophobia during 







5.1.8.9 Osmophobia during headache phase 
There was no difference in the presence of a postdrome amongst those with osmophobia during 
migraine attack (n=38) and those without (n=38) (Pearson Chi-Square, 0.164, df =1, P=0.685).  
Motion Sensitivity during headache phase 
There was no difference in the presence of a postdrome amongst those with motion sensitivity 











5.2 POSTD Study clinical results 
5.2.1 Study recruitment 
Approval for the study was granted on 27th February 2015. The first subject was enrolled on 15th 
April 2015. The study was completed on 8th December 2016 after hitting the completion target of 16. 
The enrolment period for each research subject included a screening plus NTG triggering visit. 
Subjects who had a successful triggered migraine on the first study visit were invited for two further 
scanning visits. Subjects who did not develop a migraine following NTG triggering, were excluded 
from further participation in the study. 
 
Figure 13. Screening figures. 
Two hundred and thirty-five subjects contacted to take part in the study. Eighty-five percent were 
female (n=199) and 15 were male (n= 36). Following telephone screening, 35% were eligible to take 
part (n=81). 
 
Out of the 81 eligible subjects, 46 subjects proceeded to attend the screening and triggering visit 
(Visit 1).  Thirty-eight subjects had a successful NTG triggered migraine attack. Out of the 38 
subjects, one subject had a short time interval between premonitory symptoms and migraine 






excluded. One subject had a titanium jaw plate which would have affected the quality of the ASL 
images and hence was excluded. Thirty-six subjects proceeded in the study and were invited for a 
further two visits that involved ASL MRI scans. Sixteen subjects completed all the study visits (three 
in total) and thereby meeting the study completion target. ASL MRI scans from these subjects over 
the course of triggered attacks during the study visits were procured and the alterations in the 
cerebral blood flow during different phases of a migraine attack were analysed.  
 
5.2.2 Demographics 
There was a total of 14 females and 2 male subjects, excluding any gender analysis. The age range of 
the study cohort was 18-49 years with a mean age of 35. 
5.2.3 Migraine Characteristics  
 
Ten subjects had migraine without aura, 4 subjects had migraine with aura and 2 subjects had 
chronic migraine as per the ICHD-3beta criteria (Headache Classification Committee of the 
International Headache, 2013). The subjects had between 1-22 headache days per month with a 
mean of 9 headache days per month. The subjects had suffered from migraine from between 3 years 




Twelve subjects were right handed and 4 were left handed. 
 
 
5.2.5 Migraine Associated features 
 
Of the subjects, 94% (15/16) gave a history of photophobia with their attacks. Similarly, 94% (15/16) 
reported phonophobia with their attacks, while 81% (13/16) reported nausea or vomiting with their 
attacks. Osmophobia and movement sensitivity was reported in 81% (13/16) with their attacks. At 
least one CAS was reported in 69% (11/16) with their migraine attacks, while 50% (8/16) reported 
cranial allodynia with their attacks. All the patients reported the presence of premonitory and 











Not present 6 
Phonophobia (%) 
Present 94 
Not present 6 
Nausea or vomiting (%) 
Present  81 
Not present 19 
Osmophobia (%) 
Present 81 
Not present 19 
Table 9. Baseline migraine associated features. 
5.2.6 Migraine Triggers  
Subjects in the study reported various potential triggers for their migraine attack (see Table 10). 
None of the female subjects in this cohort reported menstruation as a trigger for their migraine 
attacks.  
Stress 56 
Bright light 50 
Lack of sleep 50 
Alcohol 25 
Loud sound 19 
Strong smells 19 
Oversleeping 19 
Stormy weather 19 
Dehydration 13 
Missing meals 6 
Exertion 6 







5.2.7 Acute Medications  
One subject took 2.5 mg frovatriptan prn for acute migraine attacks. One subject took almotriptan 
12.5mg prn for acute migraine attacks. Six subjects took 50 mg of sumatriptan prn for acute 
migraine attacks. One subject took aspirin prn for acute migraine attacks. Ten subjects took 1-gram 
paracetamol prn for acute migraine attacks. Seven subjects took 400mg ibuprofen prn for acute 
migraine attacks.  
 
5.2.8 Current Preventives 
Five subjects were on migraine preventives at the time of the study. They were asked to continue 
with the drugs for the duration of the study and advised not to make any dose adjustments lest the 
adjustments lead to any alteration in rCBF values in ASL. Two subjects were on pizotifen. One subject 
each was taking amitriptyline, candesartan and propranolol. 
 
5.2.9 Previous Preventives  
Two subjects had taken gabapentin in the past for prevention. Four subjects were on Amitriptyline in 
the past. One subject was on pizotifen in the past. Four subjects were on propranolol in the past.  
 
5.2.10 Family History 
Out of the 16 subjects in the study, 14 (88%) reported a family history of migraine. 
 
5.2.11 MIDAS scores 
The MIDAS scores of subjects taking part in the study varied from 11 to 201, with a mean score of 
33. 
 
5.2.12 NTG dose 
 
From previous studies, the recommended NTG dose to trigger a migraine was calculated to be 0.5 
microgram/kg/minute over 20 minutes (Iversen et al., 1989). The total NTG dose used in the study 
























1 F 49 14 29 sumatriptan None propranolol Yes 








3 M 26 1 6 
aspirin 
paracetamol 
None propranolol Yes 




None None Yes 
5 F 36 4 24 rizatriptan candesartan None Yes 
6 F 35 5 22 sumatriptan pizotifen None Yes 




amitriptyline None Yes 







9 F 25 4 3 sumatriptan propranolol pizotifen Yes 
10 F 43 2 23 
rizatriptan 
naproxen 
None None No 
11 M 42 6 22 sumatriptan None None Yes 




13 F 37 10 23 
paracetamol 
ibuprofen 
pizotifen amitriptyline No 
14 F 27 10 15 
paracetamol 
ibuprofen 
None None Yes 
15 F 30 7 20 
paracetamol 
ibuprofen 
None None Yes 
16 F 27 5 17 
paracetamol 
ibuprofen 
None None Yes 







5.2.13 Premonitory phase  
 
Patients receiving NTG to trigger a migraine typically report a bimodal headache pattern. Firstly, 
they report a dull band like featureless headache related to NTG which settles in a few minutes and 
then from previous studies, approximately 75% of subjects go on to develop a migraine headache 
(Afridi et al., 2004b). The first triggered visit did not involve imaging whereas subjects underwent 
triggering (or placebo infusion) and imaging on the subsequent two visits. In our study, subjects 
developed a NTG headache within 1-6 minutes from the onset of NTG infusion (Mean onset 4 mins; 
SE 1.5) during the first triggered visit and within 1-10 minutes from the onset of the NTG infusion 
(Mean onset 4 mins; SE2.3) at the second triggered visit. The mild NTG headache lasted for 17  10 
mins (meanSE) during the first triggered (non-scanning visit) and 18  8 min (meanSE) during the 
second triggered (scanning) visit. For the purposes of the study, we set the onset of premonitory 
phase as the time of onset of three or more premonitory symptoms. The median onset of 
premonitory symptoms occurred at 20 minutes (IQR=8-40) at the first triggered visit and at 15 
minutes (IQR=5-28) at the second triggered visit.  
 
5.2.14 Postdrome Onset 
 
At the onset of moderate to severe headache at the first triggered visit, subjects received either 6mg 
sumatriptan subcutaneously or 1-gram intravenous aspirin to render them headache free and 
induce the postdrome phase. The postdrome was induced within a median time of 150 minutes 
(IQR=135-192) from the onset of NTG infusion at the first triggered visit and 212 minutes (IQR=184-
265) from the onset of NTG infusion at the second triggered visit.  
 
5.2.15 Premonitory symptoms 
 
During all the visits, subjects were asked regarding various premonitory symptoms after the 
initiation of NTG triggering. Subjects did not report premonitory, headache or postdrome symptoms 

















Movement sensitivity 34% 
Phonophobia 31%, 
Increased urinary frequency 19% 
Irritability 19% 
Speech difficulty 19% 
Visual Blurring 17% 
Depressed Mood 13% 
Gastric Discomfort 6% 
Elevated Mood 6% 
Food Craving 6% 
Table 12. Premonitory symptoms reported in the 16 subjects across two NTG triggered visits 
 
5.2.16 Postdrome Symptoms 
Once the throbbing headache ceased, subjects developed multiple non-headache related symptoms, 
with tiredness, concentration difficulty and head discomfort the most common reported symptoms 






































Cranial Allodynia 22% 
Eye Discomfort 13% 
 











Nasal Stuffiness 7% 
Feeling of Dread 3% 
Feeling Drunk 3% 








5.2.17 Cognitive Assessments in the Postdrome 
Much of the focus in migraine research and management has been centred around the throbbing 
pain. However various non-headache symptoms experiences in the postdrome, contribute to the 
disability and suffering of migraineurs (Bose and Goadsby, 2016). Various studies have shown that 
cognitive symptoms are commonly reported in the postdrome (Kelman, 2006; Giffin et al., 2016). 
Although studies exist that look into various cognitive domains during a migraine attack (Gil-Gouveia 
et al., 2016), the cognitive symptoms and dysfunction reported in the postdrome have not been 
objectively assessed. Previous studies relied on retrospective assessment of postdrome symptoms 
using diary based self-reporting or prospective assessment using self-reported electronic 
diaries(Giffin et al., 2005; Kelman, 2006) whereas we carried out a prospective and objective 
assessment of cognitive symptoms in the postdrome.  
 
5.2.17.1 Sustained Attention to response test (SART- See Also Page 50) 
Migraineurs commonly complain of non-headache symptoms, including cognitive symptoms in the 
postdrome (Bose and Goadsby, 2016). An electronic diary study of the migraine postdrome by Giffin 
et al., showed that 81% of the subjects evaluated had at least one non-headache symptom in the 
postdrome. Concentration difficulty was reported in 56% of the attacks (Giffin et al., 2016). To study 
the impact of cognitive symptoms in the postdrome as a secondary objective, attention was 
assessed using a sustained attention to response test (SART). Subjects were shown single digits on a 
laptop presented serially but employing a random sequence. Each digit was presented for a duration 
of 250 ms. This was followed by a diagonal cross mask which was of a total duration of 900 ms.  The 
subjects were asked to press the spacebar of the laptop for each number. The number 3 served as a 
‘no-go’ target and subjects were asked not to press the space bar when the number 3 flashed on the 
screen. The probability of number 3 flashing was set by the software as 1 in 9 (0.11) which the 
subject was not aware of. Subjects were given the opportunity to have a short practice session to 
get to grips with the keyboard before the launch of the scoring session. The total task duration was 
approximately nine minutes. Subjects where scored at baseline during their placebo scanning visit 
and during the postdrome during their triggered scanning visit to assess if there was a significant 
difference between attention at the baseline state compared to attention in the postdrome state.   
Nine out of sixteen subjects underwent the SART test at both the baseline state during a non-







5.2.17.1.1 SART Errors of commission 
This aspect of the test was to assess how well the subjects pressed the keys when the numbers apart 
from number 3 flashed (i.e. the ‘no-go’ target).  
The values of errors of commission during the baseline state ranged from 0-25% with mean=7, 
(SE8). The values of errors of commission during postdrome state ranged from 0-15% with mean=5, 
(SE8). 
5.2.17.1.2 SART Errors of omission  
This aspect of the test was to assess how well the subjects refrained from pressing the keys when 
the number 3 flashed (i.e. the ‘no-go’ target). The values of errors of omission during the baseline 
state ranged from 1-25% with mean=18, (SE8). The values of errors of omission during the 
postdrome state ranged from 12-25% with mean=21 (SE6). 
 
5.2.17.1.3 SART Mean reaction time  
The values of mean reaction time during baseline state ranged from 293.76 to 605.66 ms with 
mean=454 ms (SE113). SART mean reaction time during postdrome state ranged from 254.24 to 
628.71 with mean=484 ms (SE128). 
 
5.2.17.1.4 Statistical Analysis of SART results 
 
A paired-samples t-test was conducted to compare errors of commission between subjects at the 
baseline state compared to the postdrome state. There was no significant statistical difference in the 
scores for baseline state (mean=7, SE8) and postdrome state (mean=5, SE6); t(8) =0.696, p = 0.50.  
A paired-samples t-test was conducted to compare errors of omission between subjects at the 
baseline state compared to the postdrome state. There was no significant statistical difference in the 
scores for baseline state (mean=18, SE8) and postdrome state (mean=21, SE6); t(8) =0.652, p = 
0.53.  
A paired-samples t-test was conducted to compare mean reaction time between subjects at the 
baseline state compared to the postdrome state. There was no significant statistical difference in the 
scores for baseline state (mean=454, SE113) and postdrome state (mean=484, SE128); t(8) =1.3, p 







5.2.17.2 Karolinska sleepiness scale (KSS) 
 
With newer studies highlighting the postdrome phase, the awareness of its existence and the 
common symptoms linked to it is advancing (Kelman, 2006; Giffin et al., 2016). A common symptom 
experienced in the postdrome is somnolence. Edward Liveing made the observation that sleep 
resolved migraine in his masterpiece On Megrim (Liveing, 1872). In a study of 50 migraineurs, it was 
noted that sleep was a common way of aborting a migraine attack (Blau, 1982). Several other studies 
looking in to symptoms described in the migraine postdrome have not specifically documented 
sleep, but tiredness is the most common symptom expressed by patients in the postdrome (Kelman, 
2006; Giffin et al., 2016). Lack of sleep is also reported as a migraine trigger. 
The impact of sleepiness on the postdrome phase of migraine was assessed using a sleepiness 
indicator.  Using a validated subjective nine-point Likert-type sleepiness scale (Kaida et al., 2006) is a 
simple way of assessing sleepiness and avoids the use of intrusive and costly equipment. Previous 
studies using this scale have found a U-shaped diurnal pattern to sleep- i.e., a high sleepiness score 
in the morning and late evening (See Page 82). Sleepiness in the postdrome phase has not been 
assessed before using a sleepiness scale. The Karolinska Sleepiness scale (KSS) is a 9 point Likert-type 
scale which value ranges from ‘Extremely alert’ (score 1) to ‘Very sleepy, great effort to keep awake, 
fighting sleep’ (score 9). A comparison of the sleepiness scores of subjects between the baseline 
state and the postdrome state was done.
 







Figure 15. Karolinska Sleepiness Scale (KSS) values from a working day starting at approximately 
08:00 hours (a–d) and a day off (a, c, e). All are daytime workers, except for those in study (e), who 
are rotating shift workers on the second day off. A comparison of working days with a 1.2-year 
interval (b1, b2) for the same group. Mean ± standard error. Waking span indicated at the bottom. 




Nine out of sixteen subjects had their sleepiness scale assessed during the baseline of a non-
triggered (placebo) visit and also the postdrome phase during a triggered visit. The KSS score during 
the baseline of a non-triggered placebo visit varied from 2-7 with a median score of 3 (IQR=2-5). The 
KSS score during the postdrome phase of a NTG triggered visit varied from 5-8 with a median score 
of 8 (IQR=7-8). A Wilcoxon Signed-ranks test was conducted to compare KSS scores between 
subjects at the baseline state compared to the postdrome state. The test indicated that KSS scores 
were significantly higher in the postdrome state (median=8) than at the baseline (median= 3), (Z = 































5.2.17.3 Daily Fatigue Impact Scale (DFIS) 
Tiredness or fatigue is a common symptom reported in the postdrome phase of migraine (Kelman, 
2006; Bose and Goadsby, 2016). Though it is a common symptom, because of the difficulty for 
patients to define the symptom, it is poorly understood. A validated questionnaire to objectively 
assess fatigue was used to compare the difference between the baseline state and the postdrome 
state.  
 
Figure 17. Daily Fatigue Impact Scale (DFIS) 
 
For each factor affected by fatigue (i.e. alertness, workload, motivation for physical effort, 
maintenance of physical effort, decision making, thinking tasks, thinking slow down, limitation of 
physical activity), subjects could score between 0-4 (0-no problem, 1-mild problem, 2-moderate 
problem, 3-big problem and 4- extreme problem). A Wilcoxon Signed-ranks test to see if there was a 
statistically significant difference between the baseline state and the postdrome state.  
 
5.2.17.3.1 Fatigue impacting alertness  
 
The median DFIS alertness score during the baseline of a non-triggered placebo visit was 1 (IQR=0-2). 
The median score during the postdrome phase of a NTG triggered visit was 2 (IQR=1-2). 
A Wilcoxon Signed-ranks test was conducted to compare DFIS alertness scores between subjects at 
the baseline state compared to the postdrome state. The test indicated that DFIS scores were not 
statistically significant in the postdrome state (median=2) compared to the baseline (median= 1), (Z 








5.2.17.3.2 Fatigue impacting workload  
 
The median DFIS workload score during the baseline of a non-triggered placebo visit was 0 (IQR=0-
1). The median score during the postdrome phase of a NTG triggered visit was 2 (IQR=1-2). 
A Wilcoxon Signed-ranks test was conducted to compare DFIS workload scores between subjects at 
the baseline state compared to the postdrome state. The test indicated that DFIS scores were 
statistically significant in the postdrome state (median=2) compared to the baseline (median= 0), (Z 
= 2.16, p=0.03).  
 
5.2.17.3.3 Fatigue impacting motivation  
 
The median DFIS motivation score during the baseline of a non-triggered placebo visit was 0 (IQR=0-
1). The median score during the postdrome phase of a NTG triggered visit was 2 (IQR=1-2). 
A Wilcoxon Signed-ranks test was conducted to compare DFIS motivation scores between subjects at 
the baseline state compared to the postdrome state. The test indicated that DFIS scores were 
statistically significant in the postdrome state (median=2) compared to the baseline (median= 0), (Z 
= 1.98, p=0.04).  
 
5.2.17.3.4 Fatigue impacting maintenance of physical effort  
 
The median DFIS maintenance of physical effort score during the baseline of a non-triggered placebo 
visit was 1 (IQR=0-1). The median score during the postdrome phase of a NTG triggered visit was 1 
(IQR=1-2). A Wilcoxon Signed-ranks test was conducted to compare DFIS maintenance of physical 
effort scores between subjects at the baseline state compared to the postdrome state. The test 
indicated that DFIS scores were not statistically significant in the postdrome state (median=1) 
compared to the baseline (median= 1), (Z = 1.73, p=0.08).  
 
5.2.17.3.5 Fatigue impacting decision making  
 
The median DFIS decision making score during the baseline of a non-triggered placebo visit was 0 
(IQR=0-1). The median score during the postdrome phase of a NTG triggered visit was 1 (IQR=1-2). 






subjects at the baseline state compared to the postdrome state. The test indicated that DFIS scores 
were statistically significant in the postdrome state (median=1) compared to the baseline (median= 
0), (Z = 2.46, p=0.01).  
5.2.17.3.6 Fatigue impacting thinking tasks  
 
The median DFIS thinking task score during the baseline of a non-triggered placebo visit was 0 
(IQR=0-1). The median score during the postdrome phase of a NTG triggered visit was 2 (IQR=1-2). 
A Wilcoxon Signed-ranks test was conducted to compare DFIS thinking tasks scores between 
subjects at the baseline state compared to the postdrome state. The test indicated that DFIS scores 
were not statistically significant in the postdrome state (median=2) compared to the baseline 
(median= 0), (Z = 1.89, p=0.06).  
 
5.2.17.3.7 Fatigue slowing down thinking  
 
The median DFIS thinking slowdown score during the baseline of a non-triggered placebo visit was 1 
(IQR=0-2). The median score during the postdrome phase of a NTG triggered visit was 2 (IQR=1-2).  
A Wilcoxon Signed-ranks test was conducted to compare DFIS slowing down of thinking scores 
between subjects at the baseline state compared to the postdrome state. The test indicated that 
DFIS scores were not statistically significant in the postdrome state (median=2) compared to the 
baseline (median= 1), (Z = 0.99, p=0.32).  
 
5.2.17.3.8 Fatigue limiting physical activities  
 
The median DFIS physical activities limiting score during the baseline of a non-triggered placebo visit 
was 0 (IQR=0-1). The median score during the postdrome phase of a NTG triggered visit was 1 
(IQR=1-2). A Wilcoxon Signed-ranks test was conducted to compare DFIS slowing down of thinking 
scores between subjects at the baseline state compared to the postdrome state. The test indicated 
that DFIS scores were statistically significant in the postdrome state (median=1) compared to the 





















6 POSTD Study Imaging Results 
 
Sixteen subjects (14 female, 2 male) with a history of migraine (Headache Classification Committee 
of the International Headache, 2013) completed all imaging visits. Twelve subjects were right 
handed and 4 were left handed (For clinical characteristics of the subjects included in the analysis, 
see Page 74).  
 
Figure 18. Time line for scans after initiation of NTG infusion. Subjects underwent 4 scans at each study visit: 
baseline, premonitory, migraine headache and postdrome scan. T0 being the time of initiation of the NTG 
infusion. 
 
Imaging data were processed using SPM version 12 (http://www.fil.ion.ucl.ac.uk/spm) implemented 
in MATLAB (Mathworks, Inc, Sherborn, MA, USA). The high-resolution structural images were used 
to align the CBF data to MNI152 standard space [average T1 brain image constructed from 152 
normal subjects at the Montreal Neurological Institute (MNI), Montreal, QC, Canada]. Spatial 
normalization was performed by co-registering the CBF image to the T1 image. The spatial 
normalization parameters required to warp the T1 image to MNI space were estimated (via SPM 
unified segmentation) and these transformation parameters were applied to the CBF map. The data 
were spatially smoothed using an 8 mm full- width at half-maximum (FWHM) Gaussian kernel to 
accommodate for gyral variability across subjects. Group-level voxel-wise changes in regional CBF 
were calculated under the framework of the general linear model (GLM) using a random effects 
independent two-sample t-test. Significant clusters were displayed with a probability threshold of 






flow covariate correction was done using analysis of covariance (ANCOVA) and grey matter masking 
was also applied due to the low signal-to-noise ratio of ASL in white matter.  
 
6.1 Voxel Based Analysis 
 
Subjects underwent a total of 4 scans each during visit 2 and 3 one of which was a triggered visit and 
the other a placebo visit in a randomised order. The scans done at the triggered visit were done at 
baseline, onset of three or more premonitory symptoms, onset of moderate to severe migraine 
headache and finally at the onset of postdrome. Scans were done at the non-triggered visits based 
on time scales derived from the screening visit, for comparison of the scan done at time scale of 
migraine headache derived from screening visit, with scan done at time scale of postdrome derived 
from screening visit following administration of aspirin/sumatriptan. 
The scans were compared as follows: 
1. Baseline scans of all subjects compared to premonitory phase. 
2. Baseline scans of all subjects compared to migraine headache. 
3. Baseline scan of all subjects compared to postdrome phase. 
4. Postdrome scans of all subjects compared to premonitory phase. 
5. Migraine headache scans of all subjects compared to postdrome. 
6. Non-triggered (placebo) visit scan comparisons where, comparison of all scans done at the time 
onset of migraine headache derived from screening visit, with the scan done at the comparable time 
of postdrome, derived from screening visit following administration of aspirin/sumatriptan to assess 
qualitatively alterations in rCBF related to aspirin/sumatriptan and diurnal variation (Hodkinson et 
al., 2014) (See Page 52, 59 and Figure 19).  
Cluster statistics were used to identify statistically significant changes in CBF. Clusters were 
corrected for multiple comparison based on cluster extent (p 0.05), from a cluster-forming threshold 








Figure 19. Triggered visit scan comparisons. 1. Baseline scans of all subjects compared to 
premonitory phase 2. Baseline scans of all subjects compared to migraine headache. 3. Baseline 
scan of all subjects compared to postdrome phase. 4. Postdrome scans of all subjects compared to 









Figure 20. Non-triggered (placebo) visit scan comparison to qualitatively assess alterations in rCBF 
related to aspirin/sumatriptan and diurnal variation 
 
6.1.1 Baseline scans compared to premonitory phase scans: 
There was increased rCBF over the right and left superior frontal, medial frontal, bilateral anterior 
cingulate with peak increase over the left medial frontal gyrus (P<0.001) at a whole brain analysis 
level in the premonitory phase compared to the baseline state. There was also a reduction in rCBF in 
the premonitory phase over the right middle occipital gyrus, right middle temporal gyrus, lingual 
gyrus and cuneus, with a peak reduction over the right inferior occipital gyrus (P=0.018) compared 
to the baseline state. With small volume correction, (sphere set at 12mm radius volume of Interest, 
VOI), there was increased rCBF over the posterior cingulate and superior frontal gyrus with a peak 
increase over the posterior hypothalamus (P=0.046). No areas of reduction in rCBF were seen in the 































Figure 21. Increased rCBF in the premonitory phase compared to baseline at a whole brain level 





















Figure 22. Increased rCBF in the premonitory phase compared to baseline at whole brain level 







Figure 23. Increased rCBF in the premonitory phase compared to baseline at whole brain level 
(Sagittal sections). Figure 21, 22 and 23 show increased rCBF over the right and left superior 
frontal, medial frontal, bilateral anterior cingulate with peak increase over the left medial frontal 
gyrus (P<0.001) at a whole brain analysis level. The colour bar on the right indicates the colour 
coding of the T-scores. 
 
Figure 24. Reductions in rCBF the premonitory phase compared to baseline at a whole brain level. (Axial, 
sagittal and coronal sections) over the right middle occipital gyrus, right middle temporal gyrus, lingual gyrus 
and cuneus, with a peak reduction over the right inferior occipital gyrus (P=0.018). The colour bar on the 








Figure 25. Increased rCBF in the premonitory phase compared to baseline following small volume 




Figure 26. Increased rCBF in the premonitory phase compared to baseline following small volume 
correction (Coronal sections). Figures 25 and 26- Following small volume correction, (sphere set at 
12 mm radius volume of Interest, VOI), additional areas of increased rCBF along with those seen at 
a whole brain level analysis, were picked up over the posterior cingulate and posterior 
hypothalamus with a peak increase over the posterior hypothalamus (P=0.046). The colour bar on 







6.1.2 Baseline scans compared to migraine headache scans:  
 
There was increased rCBF over the medial frontal gyrus, superior frontal gyrus, inferior frontal gyrus, 
midbrain, hypothalamus, thalamus and cingulate gyrus with peak increase over the right superior 
frontal gyrus (P=0.001) at a whole brain analysis level, in the migraine headache phase compared to 
baseline scans. No further significant changes were observed following small volume correction.  
 
 
Figure 27. Increased rCBF in the migraine headache phase compared to baseline at whole brain 








Figure 28. Increased rCBF in the migraine headache phase compared to baseline at whole brain 
level (Coronal sections). The colour bar on the right indicates the colour coding of the T-scores. 
 
 
Figure 29. Increased rCBF in the migraine headache phase compared to baseline at whole brain 
level (Sagittal sections). Figures 28, 29 and 30 show increased rCBF over the medial frontal gyrus, 
superior frontal gyrus, inferior frontal gyrus, midbrain, hypothalamus, thalamus and cingulate 
gyrus with peak increase over the right superior frontal gyrus (P=0.001) compared to baseline 










6.1.3 Baseline scans compared to postdrome phase scans:  
 
There was a reduction in rCBF over the superior temporal gyrus, middle temporal gyrus, superior 
frontal, medial frontal gyrus, Insula, precentral gyrus, inferior frontal gyrus, inferior temporal gyrus, 
lingual gyrus, cingulate gyrus with peak reduction over the Left precentral gyrus (P<0.001) at a whole 
brain analysis level in the postdrome phase compare to baseline. Small volume correction did not 
yield additional areas. No increase in rCBF were observed. 
 
 
Figure 30. Reduction in rCBF in the postdrome phase compared to baseline at whole brain level and 
following small volume correction. (Sagittal, coronal and axial sections). Figures show reduction in rCBF over 
the superior temporal gyrus, middle temporal gyrus, superior frontal, medial frontal gyrus, Insula, precentral 
gyrus, inferior frontal gyrus, inferior temporal gyrus, lingual gyrus, cingulate gyrus with peak reduction over 
the Left precentral gyrus (P<0.001) at a whole brain analysis level. Small volume correction did not yield 








6.1.4 Postdrome scans compared to premonitory scans: 
There was a reduction in rCBF over the superior frontal gyrus, medial frontal gyrus, middle frontal 
gyrus, putamen, superior temporal gyrus, middle temporal gyrus, inferior temporal gyrus, thalamus, 
hypothalamus, midbrain, posterior cingulate, anterior cingulate, claustrum and a peak reduction in 
rCBF over the left superior temporal gyrus (P<0.001) at a whole brain analysis level in the postdrome 
phase compared to premonitory phase. Small volume correction showed additional areas of 
reduction in rCBF over the frontal medial orbital gyrus, Insula, caudate, with peak reduction in rCBF 
over the left medial globus pallidus (P=0.027, sphere set at 12mm radius of VOI) along with areas 
with reductions seen in rCBF at a whole brain level analysis. There was a preponderance of the 
reductions in rCBF to the left cerebral hemisphere, but this study was not designed to look at 
laterality of the changes. 
 
 
Figure 31. Reduction in rCBF in the postdrome phase compared to the premonitory phase at a 
whole brain level (Axial, sagittal and coronal sections). Figures 34 show reduction in rCBF over the 
superior frontal gyrus, medial frontal gyrus, middle frontal gyrus, putamen, superior temporal 
gyrus, middle temporal gyrus, inferior temporal gyrus, thalamus, hypothalamus, midbrain, 
posterior cingulate, anterior cingulate, claustrum and a peak reduction in rCBF over the left 
superior temporal gyrus (P<0.001) at a whole brain analysis level in the postdrome phase 
compared to the premonitory phase. The colour bar on the right indicates the colour coding of the 
T-scores. 
 
6.1.5 Postdrome scans compared with migraine headache:  
There was a reduction in rCBF over the pons, midbrain, superior temporal gyrus, middle temporal 
gyrus, inferior temporal gyrus, cingulate gyrus, precuneus, inferior parietal lobule, superior frontal 
gyrus, medial frontal, inferior frontal gyrus, precentral gyrus, post central gyrus and a peak reduction 
in rCBF over the left superior temporal gyrus (P<0.001) at a whole brain analysis level in the 
postdrome phase compared to migraine headache phase. Small volume correction did not yield any 







Figure 32. Reduction in rCBF in the postdrome phase compared to the headache phase at a whole brain 
(Axial, sagittal and coronal sections). Figures show a reduction in rCBF over the pons, midbrain, superior 
temporal gyrus, middle temporal gyrus, inferior temporal gyrus, cingulate gyrus, precuneus, inferior parietal 
lobule, superior frontal gyrus, medial frontal, inferior frontal gyrus, precentral gyrus, post central gyrus and 
a peak reduction in rCBF over the left superior temporal gyrus (P<0.001) at a whole brain analysis level in 
the postdrome phase compared to migraine headache phase. Small volume correction did not yield any 
additional areas of change in rCBF. The colour bar on the right indicates the colour coding of the T-scores. 
 
6.1.6 Non-triggered (placebo) visit scan comparisons  
Comparison of all scans done at time scale of migraine headache derived from screening visit, with 
all scans done at time scale of postdrome derived from screening visit following administration of 
aspirin/sumatriptan on the placebo visit (See Figure 20). Reduction in rCBF was seen in the posterior 
cingulate on the placebo visit at corresponding time to postdrome phase compared to migraine 
headache phase, from triggered visit but does not reach significance (P=0.142). 
 
Figure 33. The corresponding time scale of migraine headache scan compared to the postdrome scan on the 
non-triggered placebo visit. Reduction in rCBF was seen in the posterior cingulate on the placebo visit at 
corresponding time to postdrome phase compared to migraine headache phase, from triggered visit but 































14 64 18 4.16 0.001 
















-8 -4 -8 3.92 0.046 
Table 15. MNI co-ordinates of areas with increased peak regional cerebral blood flow following 






























-12 34 26 8.66 <0.001 






















-46 -6 50 9.55 <0.001 
Premonitory vs 
postdrome 
Left medial globus 
pallidus 
-10 -2 0 3.89 0.027 
Table 17.MNI co-ordinates of areas with reduction in peak regional cerebral blood flow following 







6.2 Region of interest (ROI) analysis 
Certain key brain regions were selected for further investigation, based on previous functional 
imaging studies in migraine; and on the relevance of those functional areas for the perception of 
pain. The key brain areas include the hypothalamus, the pons, the midbrain, the thalamus, the 
anterior cingulate cortex and the insula (Maniyar et al., 2014a; Hodkinson et al., 2015b; Schulte and 
May, 2016b). Mean CBF from these key areas during the baseline, premonitory, migraine headache 
and postdrome phases were extracted and paired t-test comparisons were done to see if there were 
any significant alterations in rCBF. Results were tested at a significance threshold < 0.05. 
6.2.1 Hypothalamus 
No statistically significant changes in rCBF were seen in the hypothalamus with ROI analysis in the 













Pair 1 a. Baseline 46.49 16 6.80954 1.70238 .197 
 b. Premonitory 48.18 16 8.32212 2.08053  
Pair 2 a. Baseline 46.49 16 6.80954 1.70238 .426 
 b. Headache 47.26 16 6.77143 1.69286  
Pair 3 a. Baseline 46.49 16 6.80954 1.70238 .894 
 b. Postdrome 46.63 16 6.16587 1.54147  
Pair 4 a. Headache 48.18 16 8.32212 2.08053 .173 
 b. Postdrome 46.63 16 6.16587 1.54147  
Pair 5 a. Premonitory 47.26 16 6.77143 1.69286 .373 
 b. Postdrome 46.63 16 6.16587 1.54147  
Table 18. ROI analysis hypothalamus 
6.2.2 Pons 
No statistically significant changes in rCBF was seen in the pons with ROI analysis in the premonitory, 












Pair 1 a. Baseline 44.4368 16 7.01249 1.75312 .788 
 b. Premonitory 44.0424 16 10.28714 2.57178  
Pair 2 a. Baseline 44.4368 16 7.01249 1.75312 .963 
 b. Headache 44.4697 16 6.56484 1.64121  
Pair 3 a. Baseline 44.4368 16 7.01249 1.75312 .529 
 b. Postdrome 43.8677 16 6.13102 1.53275  
Pair 4 a. Headache 44.4697 16 6.56484 1.64121 .367 
 b. Postdrome 43.8677 16 6.13102 1.53275  
Pair 5 a. Premonitory 44.0424 16 10.28714 2.57178 .911 
 b. Postdrome 43.8677 16 6.13102 1.53275  








No statistically significant changes in rCBF was seen in the midbrain with ROI analysis in the 












Pair 1 a. Baseline 48.0671 16 7.44398 1.86099 .265 
 b. Premonitory 49.1182 16 9.40729 2.35182  
Pair 2 a. Baseline 48.0671 16 7.44398 1.86099 .736 
 b. Headache 48.3470 16 8.01662 2.00415  
Pair 3 a. Baseline 48.0671 16 7.44398 1.86099 .758 
 b. Postdrome 47.7573 16 7.01158 1.75289  
Pair 4 a. Headache 48.3470 16 8.01662 2.00415 .418 
 b. Postdrome 47.7573 16 7.01158 1.75289  
Pair 5 a. Premonitory 49.1182 16 9.40729 2.35182 .253 
 b. Postdrome 47.7573 16 7.01158 1.75289  








6.2.4 Left thalamus  
 
No statistically significant changes in rCBF was seen in the left thalamus with ROI analysis in the 













Pair 1 a. Baseline 46.7497 16 7.81486 1.95372 .093 
 b. Premonitory 48.5809 16 9.68338 2.42084  
Pair 2 a. Baseline 46.7497 16 7.81486 1.95372 .450 
 b. Headache 47.3642 16 8.40972 2.10243  
Pair 3 a. Baseline 46.7497 16 7.81486 1.95372 .824 
 b. Postdrome 46.5753 16 6.96955 1.74239  
Pair 4 a. Headache 48.5809 16 9.68338 2.42084 .067 
 b. Postdrome 46.5753 16 6.96955 1.74239  
Pair 5 a. Premonitory 47.3642 16 8.40972 2.10243 .248 
 b. Postdrome 46.5753 16 6.96955 1.74239  
Table 21. ROI analysis left thalamus 
 
 
6.2.5 Right thalamus 
 
No statistically significant changes in rCBF was seen in the right thalamus with ROI analysis in the 












Pair 1 a. Baseline 45.4107 16 7.24481 1.81120 .158 
 b. Premonitory 46.9095 16 8.79185 2.19796  
Pair 2 a. Baseline 45.4107 16 7.24481 1.81120 .379 
 b. Headache 46.3842 16 7.97035 1.99259  
Pair 3 a. Baseline 45.4107 16 7.24481 1.81120 .664 
 b. Postdrome 45.8432 16 6.48616 1.62154  
Pair 4 a. Headache 46.3842 16 7.97035 1.99259 .543 
 b. Postdrome 45.8432 16 6.48616 1.62154  
Pair 5 a. Premonitory 46.9095 16 8.79185 2.19796 .391 
 b. Postdrome 45.8432 16 6.48616 1.62154  








6.2.6 Anterior cingulate cortex 
 
Statistically significant reduction in rCBF was seen in anterior cingulate cortex (ACC) during the 
postdrome phase compared to the migraine headache (P=0.011). The mean rCBF in the ACC during 
the migraine headache phase was 55 8 ml/min/100ml tissue and mean rCBF in the ACC during the 
postdrome phase was 53 7 ml/min/100ml tissue. 
 
Statistically significant reductions in rCBF were seen in anterior cingulate cortex (ACC) during the 
postdrome phase compared to the premonitory phase (P=0.002). The mean rCBF in the ACC during 
the premonitory phase was 58 ml/min/100ml tissue (SE9) and mean rCBF in the ACC during the 













Pair 1 a. Baseline 54.5048 16 8.06952 2.01738 .066 
 b. Premonitory 57.8716 16 9.32448 2.33112  
Pair 2 a. Baseline 54.5048 16 8.06952 2.01738 .709 
 b. Headache 54.9251 16 7.92511 1.98128  
Pair 3 a. Baseline 54.5048 16 8.06952 2.01738 .115 
 b. Postdrome 52.6568 16 6.70438 1.67609  
Pair 4 a. Headache 54.9251 16 7.92511 1.98128 .011 
 b. Postdrome 52.6568 16 6.70438 1.67609  
Pair 5 a. Premonitory 57.8716 16 9.32448 2.33112 .002 
 b. Postdrome 52.6568 16 6.70438 1.67609  









Statistically significant reductions in rCBF were seen in the Insula in the postdrome phase compared 
to the baseline (P=0.03). The mean rCBF in the Insula during the baseline phase was 57  10 
ml/min/100ml tissue and mean rCBF in the Insula during the postdrome phase was 54 7 
ml/min/100ml tissue.  
 
Statistically significant reductions in rCBF were seen in the insula in the postdrome phase compared 
to the migraine headache phase (P=0.009). The mean rCBF in the Insula during the migraine 
headache phase was 57 2 ml/min/100ml tissue and mean rCBF in the Insula during the postdrome 
phase was 54 7 ml/min/100ml tissue. 
 
Statistically significant reductions in rCBF were seen in the Insula in the postdrome phase compared 
to the premonitory phase (P=0.002). The mean rCBF in the Insula during the premonitory phase was 
59 ml/min/100ml tissue (SE10) and mean rCBF in the Insula during the postdrome phase was 54 












Pair 1 a. Baseline 56.7447 16 9.89417 2.47354 .307 
 b. Premonitory 58.5857 16 9.80808 2.45202  
Pair 2 a. Baseline 56.7447 16 9.89417 2.47354 .857 
 b. Headache 56.5265 16 9.02621 2.25655  
Pair 3 a. Baseline 56.7447 16 9.89417 2.47354 .030 
 b. Postdrome 53.8688 16 7.24383 1.81096  
Pair 4 a. Headache 56.5265 16 9.02621 2.25655 .009 
 b. Postdrome 53.8688 16 7.24383 1.81096  
Pair 5 a. Premonitory 58.5857 16 9.80808 2.45202 .002 
 b. Postdrome 53.8688 16 7.24383 1.81096  

























7 Seasonal variation in NTG Triggering 
 
Since the introduction of intravenous NTG for triggering migraine, studies have shown that migraine 
can be induced in about 75% of migraineurs. No study has looked into the variability of NTG induced 
migraine in association with weather changes. 
 
Weather has a profound influence on our day to day life. It has an effect on our function, clothing, 
commute to work and more importantly, on illnesses that may affect us. Seasonal variation has been 
reported in various neurological and psychological illnesses (Seregi et al., 2016; Sipila et al., 2016; 
Watad et al., 2016; Wynchank et al., 2016) . Why there should a seasonal variation in illnesses has 
not been fully elucidated but several factors either on their own or in combination can be 
considered. Firstly, temperature has an effect on nerve conduction velocity perhaps by differential 
altering of the kinetics of sodium/potassium channel gating mechanisms (Kiernan et al., 2001). 
Secondly, differential seasonal expression of genes may affect human immunity and physiological 
functions (Dopico et al., 2015). We already know that weather influences the attacks or symptoms of 
various disorders including neurological disorders. For example, patients with multiple sclerosis can 
get worsening symptoms in the heat ( Uhthoff’s phenomenon) (Tsolaki et al., 2011). 
 
The hypothalamus may be a driver in the circannual and circadian periodicity seen in various 
disorders especially trigeminal autonomic cephalalgias, though this is not established (Holle et al., 
2011). Also, neuroimaging studies have shown activation of the hypothalamus even before the onset 
of headache in migraine (Maniyar et al., 2014a; Schulte and May, 2016b) and hence it is conceivable 
that the hypothalamus could be a key driver in the initiation and also maintenance of periodicity in 
various pain states.   
 
Seasonal variation in migraine attack frequency has been reported (Caperell and Pitetti, 2014; Shin 
et al., 2015; Pakalnis and Heyer, 2016) . There may be a select group of migraineurs sensitive to 
temperature changes associated with weather and also, the impact maybe more with certain types 
of migraine, like migraine with aura rather than migraine without aura (Alstadhaug et al., 2005).  
 
We carried out a subgroup analysis of subjects taking part in the POSTD imaging study, to see if the 
weather had any effect on NTG triggered migraine. There were 46 subjects included in this analysis. 
Sixteen subjects completed all the imaging study visits. However, there were subjects who had 















46 subjects were included in this subgroup analysis. There was a total of 82 NTG triggering visits 
within this subgroup (n = 46; mean age 35 years, range 18-49 years, 38 females). 
 
Based on simplicity and consistency, the Met Office, UK, meteorologically divides seasons over three 
monthly intervals. March, April and May constitute Spring. June, July and August constitute Summer. 




7.2.1 NTG triggering in Spring 
This period covers NTG triggering visits between April-May 2015 and April-May 2016. There was a 
total of 16 NTG triggered visits. Subjects successfully had a triggered migraine in 12 visits and did not 
trigger in four visits. The NTG trigger success rate was 75%. 
 
7.2.2 NTG triggering in Summer 
This period covers NTG triggering visits between June-August 2015 and June-August 2016. There was 
a total of 26 NTG triggered visits. Subjects successfully had a triggered migraine in 25 visits and did 
not trigger during one visit. The NTG trigger success rate was 96%. 
 
7.2.3 NTG triggering in Autumn 
This period covers NTG triggering visits between September-November 2015 and September-
November 2016. There was a total of 28 NTG triggered visits. Subjects successfully had a triggered 
migraine in 25 visits and did not trigger in 3 visits. The NTG trigger success rate was 89%. 
 
7.2.4 NTG triggering in Winter 
This period covers NTG triggering visits between December-February 2015. There was a total of 13 
NTG triggered visits. Subjects successfully had a triggered migraine in 4 visits and did not trigger in 9 
visits. The NTG trigger success rate was 31%. 
 
The overall number of NTG trigger visits across all the weathers was 82. Subjects did not have a 







Figure 34. NTG triggering rates in Winter, Spring, Summer and Autumn as a percentage. 
 
A generalised estimating equations analysis was conducted using SPSS version 23 to predict if there 
was any effect of season on NTG triggering rates. The Wald Chi square test demonstrated that 
summer has a statistically significant effect on NTG triggering rates compared to winter (P=0.034). 
Exp(B) value indicates that when NTG triggering occurs in summer as compared to winter, the odds 
ratio is 12.5. Hence summer increases NTG trigger rate by a factor of 12.5 when compared to winter. 
(Wald 2 = 5.1, P = 0.034, with df = 1). Spring did not have a statistically significant effect on NTG 
triggering rates compared to winter (Wald 2 = 0.39, P = 0.53, with df = 1). Autumn did not have a 
statistically significant effect on NTG triggering rates compared to winter (Wald 2 = 1.49, P = 0.22, 








This data clearly shows that NTG trigger rates are lowest during winter. The reasons behind this 
need further exploration. Perhaps weather changes have a profound effect on the metabolism of 
NTG impacting its nitric oxide (NO) donation, or there may be another seasonally induced variance 
such as hydration, mood, etc. that causes these differences. Another possibility is that weather 
changes can affect the conduction of nerve impulses, leading to a slowdown during winter of the 
propagation of molecular cascades triggered by NTG. Not all subjects may be susceptible, but there 
could be a select group of subjects who are exquisitely sensitive to weather changes when it comes 
to NTG induced migraine.  
 
This data may have profound implications for the conduction of future migraine research studies by 
means of NTG triggering.  Some of the possible issues to consider are: 
 
1. The issue of wasted resources for the subjects and physicians involved, when a subject does not 
trigger a migraine attack during cooler weather. 
2. It can drive up the cost of research projects due to wasted visits. 
3. It may lead to prolongation of migraine provocation model based research studies and the non-
triggered subjects will need to be replaced. 
4. There may also be weather-related effects on the speed of headache resolution after treatment 
with sumatriptan or aspirin, which are also worth further investigation. 
 
Further studies specifically designed to assess the impact of weather on NTG triggering, controlling 
for potential confounding factors like preventive medications, migraine frequency etc., need to be 
done to assess this further. It would be interesting to assess if there is a difference in brain 
activations depending on the weather with a designated imaging protocol. This knowledge would be 
vital to plan and allocate resources accordingly in both imaging based and non-imaging based 


























8 Discussion  
8.1 The migraine postdrome clinical audit  
Whether patients experienced the postdromal phase or not was well set out in the clinic records. 
This is an indication that clinicians are asking about this phase following the headache pain. It must 
be noted though that this maybe because the case notes assessed in this audit were from a tertiary 
neurology referral centre and the physicians involved in the clinic under the supervision of Professor 
Goadsby are likely to be more aware of the postdrome. Also, the patients referred to the centre may 
have a more frequent attacks or severe migraine attacks. This audit also cannot conclusively state 
that a postdrome or postdromal symptoms were not present in the non-postdrome group because 
even though they did not explicitly appear in the clinic records, there is still a chance that during 
clinic the postdrome phase was not addressed due to various factors like recall bias and lack of 
postdromal symptoms entry in patient headache diaries (Quintela et al., 2006). The issues can be 
addressed by prospective data collection and an electronic prospective diary study of postdrome 
symptoms was published after this clinical audit was undertaken (Giffin et al., 2016) . Underlying all 
of the questions about postdrome is the fact that some patients are not aware of the postdromal 
phase, as a distinct phase describing the post headache experience. This may be due to them not 
experiencing this phase, or more likely they have not heard of this terminology and therefore have 
not been able to name their experience after the headache has dissipated. Therefore, without being 
specifically asked by their neurologist, they may not volunteer symptoms.  Once they are prompted 
to speak about their experience following headache subsidence, they are able to distinguish 
between these two phases. One being the true headache pain and the other being perhaps a duller 
head discomfort with various other non-headache related symptoms, but nonetheless, just as, if not 
a more debilitating phase of feeling exhausted and ‘hung-over’. This was highlighted by Kelman 
(Kelman, 2006) who narrated one description of the 827 patients in the cohort: ‘The calm, after the 
storm’. Due to this lack of awareness, not all postdrome is reported, even when asked.  
Additionally, in rare cases where attacks were very frequent, the distinguishing of episodic and 
chronic migraine was problematic in terms of dissecting the postdrome from premonitory 
symptoms. This does bring into question whether similar brain areas are active in both these phases, 
given the striking resemblance of many of the symptoms in both these phases.  Disability and 
postdrome duration were not well recorded in the clinic records. This is an indication for 
neurologists to ask more specifically about the postdrome duration and disability aspects to aid 






the extent of the problem and its impact will guide future research into its pathophysiology and 
possible therapeutic interventions.  
There is scarcity of papers in the medical literature regarding the postdrome and much could be 
achieved with prospective studies and careful clinical observations. Population based studies are 
essential to understand the wider impact of the problem. Clear classification is an essential 
requirement to guide future research into the condition. Incorporation of this phase into clinical 
trials may help to understand the wider potential of therapeutic agents because although 
treatments like triptans may relieve headache symptoms, it appears that they do not alter the 
fundamental brainstem mechanisms responsible for the initiation and propagation of migraine 
(Weiller et al., 1995; Akerman et al., 2011). Understanding the pathophysiology behind the 
postdrome may hold the key in understanding the overall biology of migraine and to manage 







8.2 THE MIGRAINE POSTDROME ARTERIAL SPIN LABELED (ASL) MRI IMAGING STUDY (POSTD) 
This study has revealed the activations of key brain areas like the superior frontal, medial frontal, 
anterior cingulate, posterior cingulate and posterior hypothalamus in the premonitory phase do not 
remain persistently activated in the postdrome phase. Though these structures appear integral to 
initiation and propagation of neural activations which could potentially modulate inhibitory effect on 
the trigeminocervical complex (TCC) in a top-down manner, the findings from this study suggest 
other mechanisms responsible for postdrome symptoms. Activation of the hypothalamus in the 
premonitory phase has been demonstrated in previous studies both with PET (Maniyar et al., 2014a) 
and BOLD MRI studies (Schulte and May, 2016b), which shows the consistency of ASL technique and 
the reliability of the involvement of this brain area. The role of the hypothalamus in the initiation of 
migraine is clearly a subject of further research. It also remains to be elucidated whether activation 
of hypothalamus is specific to the migraine process or whether it can occur in other pain conditions, 
heralding the onset of acute severe pain by merely being a component of nociceptive pathways.  
 
The common symptoms experienced by subjects in the premonitory phase during the study include 
neck stiffness, fatigue, photophobia, concentration difficulty, thirst, nausea, yawning, movement 
sensitivity, phonophobia, increased urinary frequency, irritability, speech difficulty, visual blurring, 
depressed mood, gastric discomfort, elevated mood, and food craving. Hypothalamic activation may 
explain some of the symptoms by virtue of its dopaminergic connections and possibly related to 
reduction in vasopressin (Melis and Argiolas, 1999; Krowicki and Kapusta, 2011). Involvement of the 
frontal brain regions may explain the various other symptoms experienced in the premonitory phase 
like concentration difficulty, irritability, speech difficult, and mood changes  (Thompson-Schill et al., 
2009).  
 
This study showed that there was increased rCBF over the frontal gyrus, midbrain, hypothalamus, 
thalamus and cingulate gyrus during the migraine headache phase. The brain areas activated in the 
migraine headache phase have similarly been seen in previous neuroimaging studies of both 
spontaneous and provoked migraine models (Weiller et al., 1995; Afridi et al., 2005b; Kato et al., 
2010). Previous voxel-based morphometry studies in migraine subjects, have shown significant gray 
matter reduction in brain areas that are thought to be involved in pain modulation such as the 
temporal gyrus, parietal Operculum, frontal gyrus, and precentral gyrus. Also, chronic migraineurs 
were shown to have a reduction in gray matter mainly in the ACC (Kim et al., 2008; Valfre et al., 
2008). This study was not designed to assess the reduction of grey matter but has picked up some of 






repeated attacks will have any effect on grey matter alterations in rCBF or structural integrity 
remains to be studied with ASL MRI with a designated protocol.  
 
The common postdrome symptoms reported by subjects in this study cohort were:  tiredness, 
concentration difficulty, head discomfort, neck stiffness, hangover, generalised weakness, feeling of 
relief, photophobia, elevated mood, malaise, thirst, movement sensitivity, cranial allodynia, eye 
discomfort, internal vertigo, nausea, phonophobia, gastric discomfort, depressed mood, nasal 
stuffiness, feeling of dread and feeling drunk. Some of the symptoms complained by subjects in this 
phase were similar to the ones reported in the premonitory stage and hence it would be reasonable 
to assume that the brain activations in both these phases maybe similar. However, this study has 
conclusively shown that postdrome symptoms are associated with near global reduction in rCBF 
over the superior frontal gyrus, medial frontal gyrus, middle frontal gyrus, putamen, superior 
temporal gyrus, middle temporal gyrus, inferior temporal gyrus, thalamus, hypothalamus, midbrain, 
posterior cingulate, anterior cingulate, claustrum, with a peak reduction in rCBF over the left 
superior temporal gyrus at a whole brain analysis level in the postdrome phase compared to the 
premonitory phase. There was a preponderance of the reductions in rCBF to the left cerebral 
hemisphere, but this study was not designed to look at laterality of the changes. What this has 
demonstrated for the first time in literature, is that, the symptoms experienced in the postdrome 
phase are related to a near global reduction in rCBF and there was no brain area found to be 
activated in this stage. The multitude of symptoms experienced in this phase can now be explained 
by a near global brain shut down as it tries to ‘re-boot’ itself from a migraine headache attack. It is 
worth stressing that this near-global reduction is independent of the effects of the treatment as 
evidenced by the results obtained from the non-triggered visit (See Figure 33).  This reduction is also 
present even when the global CBF over the whole brain is added as a covariate, showing the 
significance of the perfusion characteristics of the substrates involved. 
 
Global reduction in CBF has been shown to be associated with chronic fatigue syndrome, a 
complicated and controversial disease where fatigue/tiredness is a prominent feature (Yoshiuchi et 
al., 2006; Biswal et al., 2011). An ASL study looking into chronic fatigue syndrome found reduction in 
CBF in a global distribution especially involving the frontal, parietal and temporal regions (Yoshiuchi 
et al., 2006; Biswal et al., 2011). However, given the prolonged duration of fatigue in chronic fatigue 
syndrome as opposed to postdrome, the pathophysiological basis for both these conditions are likely 
to be different (Clayton, 2015). Moreover, in the postdrome phase additional areas were involved 






to postdrome, putamen, thalamus, hypothalamus, midbrain and posterior cingulate when 
postdrome scans were compared to premonitory scans. This indicates involvement of a different and 
widespread neural network in postdrome as opposed to chronic fatigue syndrome. CBF changes 
associated with mood changes, robustly induced in healthy adolescents has been reported. The 
authors reported increased rCBF in the limbic regions following happy mood induction procedures 
(Mikita et al., 2015). The POSTD study has shown significant involvement of limbic structures in the 
postdrome that can explain some of the mood changes reported in the postdrome. To further study 
the neural networks associated with mood changes in the postdrome, it would require a designated 
protocol and careful patient selection of those having prominent mood changes within the 
postdrome phase.  
 
The pathophysiological basic of the postdrome, hence cannot be explained by persistent activation 
of similar networks seen in the postdrome phase and other mechanisms need to be considered. The 
locus coeruleus is a brainstem noradrenergic nucleus located in the dorsal pontine tegmentum. This 
nucleus provides the major source of norepinephrine (NE) to the cerebrum, brainstem, cerebellum 
and spinal cord. The existence of reciprocal circuits between this nucleus, the neocortex, 
diencephalon, limbic system, and spinal cord emphasise its widespread impact within the neuraxis 
(Mai and Paxinos, 2012). The locus coeruleus noradrenergic system is one of the first systems that 
gets involved during a stressful event. It is involved in a broad range of physiological and 
psychological events like pain processing, behavioural modification and stress reactivity (McCall et 
al.). Functional imaging studies have shown activation of the dorsal pons in premonitory and 
migraine headache phases (Weiller et al., 1995; Afridi et al., 2004a; Afridi et al., 2005c; Maniyar et 
al., 2014a). This activation might include the locus coeruleus (Maniyar et al., 2014a), leading to 
widespread vasoconstriction mediated by an 2-adrenoceptor mechanism (Goadsby et al., 1982, 
1983, 1985). The near global reductions in rCBF seen in the postdrome can be explained by 
widespread vasoconstriction via 2-adrenoceptor mechanism through activation of brain stem 
nuclei. This may serve as a pain modulatory mechanism but as a consequence, lead to the protean 
postdromal symptoms resulting from a near global reduction in rCBF.  
 
Another mechanism that can potentially explain the reductions in rCBF in the postdrome is the 
phenomenon of cortical spreading depression (CSD). This bioelectrical phenomenon was first 
described by Leao (AAP, 1944; Leao, 1947) who demonstrated a wave of spreading suppression of 
spontaneous EEG activity when electrically stimulating rabbit cortex.  CSD usually silences 






pathophysiological states like hypoglycaemia, hypoxia and ischemia, CSD can occur spontaneously 
and can be prolonged in nature (Kraig and Nicholson, 1978). There is increased susceptibility to CSD 
when astroglial function is hampered (Largo et al., 1997). Electrophysiological studies demonstrate 
that in migraineurs, a cortical and possibly subcortical dysfunction may explain increased 
susceptibility to CSD (Schoenen et al., 2003; Lauritzen et al., 2011). CSD is preceded by a fast 
network of oscillations (AAP, 1944) suggesting brief hyperexcitability (AAP, 1944). This is followed by 
complete suppression of neuronal activity, lasting several minutes, followed by complete recovery 
(Leao, 1947). Hadjikhani et al., used functional imaging to support CSD as the generator of migraine 
aura (Hadjikhani et al., 2001). Persistent hypoperfusion following CSD has been demonstrated and 
hence corroborates the notion that the perfusion changes of migraine may be pathophysiologically 
related to spreading depression (Lauritzen, 1984). The CSD phenomenon can potentially explain the 
neuronal activations initially seen in the premonitory and migraine headache phase followed by the 
persistent near global hypoperfusion seen in the postdrome. However, this is an area that needs 







8.3 Cognitive assessments in the POSTD Imaging study 
The numbers used to study attention in this study are small, but within the timeframe of this MD 
project; and given the recruitment resources available, it was not possible to increase it. Larger 
numbers may be needed to get a statistically significant difference in assessing the postdrome phase 
using the SART test. Nevertheless, the test is based on sound principles and avoids practice and 
order effect. Future studies specifically designed to assess attention in postdrome phase using the 
SART test maybe needed to objectively assess attention.  
 
The number of patients used to study sleepiness in this study, once again is small. The scale has not 
been used to assess sleepiness in the various migraine states before. From previous studies, the 
typical KSS values for healthy alert individuals would be between 3 and 4. Various factors like, the 
time of the day, medications, disease states, stress etc. can affect the scores (Akerstedt et al., 2014). 
In this study, the median KSS score (8) during the postdrome phase was significantly higher (P=0.01) 
than the median baseline KSS score (3). This would fit with the common clinical scenario and as 
often seen in clinical studies into the postdrome, where sleepiness is commonly reported.  The scale 
is easy to self-administer by subjects and is quick to perform. This scale holds promise as a reliable 
and simple tool to assess sleepiness over the various phases of migraine. 
 
Fatigue in the postdrome had a statistically significant effect on reduction of workload, motivation, 
decision making and limitation of physical activity. The DFIS is useful to assess the short-term impact 
of fatigue in the postdrome phase of migraine and larger studies specifically designed to assess 
























9.1 Migraine postdrome clinical audit 
 
The data convincingly demonstrates that the postdromal phase has a profound impact on 
migraineurs within our clinical cohort. The disability related to migraine is not limited to the 
headache phase and includes the postdrome. Although the presence of the postdrome was regularly 
asked about in clinic, its duration was not. Duration should be routinely recorded going forward. 
While over half of the postdrome sufferers experienced at least one cranial autonomic symptom 
during their migraine, none were documented during the postdrome. This may be due to lack of 
direct questioning regarding presence of autonomic symptoms in the postdrome phase. 
Understanding pathophysiology of the migraine postdrome will inform how the brain behaves as the 
attack subsides and may inform interventions to shorten its duration. Functional neuroimaging may 
give us further clues regarding the neural networks involved in the postdrome to understand the 







9.2 POSTD Imaging study 
ASL MRI is a promising imaging technique to understand the neural processes involved in migraine. 
Due to its non-invasive character, it offers several practical advantages like repeatability, safety, 
complete avoidance of nuclear tracers, less requirement of a sophisticated infrastructure like PET 
and the ability to make quantitative assessments.  
 
The study shows that the symptoms experienced in the postdrome phase are associated with a near 
total reduction in rCBF and not due to activation of similar areas as those seen in the premonitory 
phase, thereby disproving my original working hypothesis which proposed that the activations brain 
regions seen in the premonitory phase would remain activated, thus giving rise to the postdrome 
symptoms. The biology behind this can potentially be explained by widespread vasoconstriction 
through a 2-adrenoceptor mechanism or CSD. Clearly this is an area that needs further research to 
explore the underlying mechanisms and neural networks involved.  
 
A significant finding is that the neural activity in regions normally associated with pain perception, 
starts before the onset of throbbing headache (i.e. in the premonitory phase) and persists beyond 
the cessation of the throbbing headache (i.e. the postdrome phase) whereas the mainstay of acute 
migraine treatments traditionally focusses on the cessation of the throbbing pain. The throbbing 
pain may represent only the tip of the iceberg when it comes to migraine symptomatology. We must 
broaden our scope of treatment beyond the onset and cessation of the throbbing pain, and target 
the neural activity, which may have a bigger impact on symptom resolution in migraine i.e.- 
targeting the root cause rather than the tip of the problem. One can anticipate that the brain 
activations detected during the course of a migraine attack, particularly during the symptomatic but 
pain free stages before and after the throbbing headache cessation, may be an appropriate target 







9.3 Study limitations 
 
The limitations of this study can be broadly discussed under the following categories: 
 
1. Limitations of the imaging technique used (i.e. ASL MRI)  
2. Limitations in the study design.  
 
ASL has an intrinsic low signal to noise ratio (SNR) though PCASL offers the best SNR. The relative 
sensitivity to motion artefacts is high (Petcharunpaisan et al., 2010; Grade et al., 2015). ASL does not 
give information regarding cerebral blood volume or mean transit time. So it is currently not possible 
to say whether alterations in rCBF with ASL could be attributed to either higher cerebral blood 
volume or increased mean transit time or both (Pollock et al., 2009). Improvements in ASL 
techniques are likely to produce better spatial and temporal resolutions in the future (Zhang et al., 
2014). 
 
One could argue whether the spontaneous and triggered migraines are one and the same (See Page 
27). Clinically, and radiologically there are several similarities of triggered and spontaneous migraine 
attacks. What happens at a molecular level remains to be elucidated and may help differentiate if 
indeed the attacks are similar or not.  
 
The lack of a control arm in the study design (healthy volunteers receiving nitroglycerin) leads to the 
question, what proportion of the observed alterations in CBF are related to NTG. Although it would 
be useful to have such a control arm, it is unlikely that the alterations in rCBF are due to 
nitroglycerin because of the short half-life of nitroglycerin and because similar alterations in 
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APPENDIX B - INCLUSION AND EXCLUSION CRITERIA FOR STUDY 
 
Inclusion criteria for the study  
Subjects needed to meet all the following inclusion criteria to be eligible for enrolment into the 
study:  
1. Subjects had to be willing to travel to and from King’s College Hospital, London, during the course 
of a day for the study visits.  
2. Subjects had to have a diagnosis of migraine with or without aura, as per the ICHD-3 beta criteria 
(Headache Classification Committee of the International Headache, 2013).  
3. Subjects were aged between 18-50 years. Subjects over 50 years were not included in the study to 
minimise any atherosclerotic changes in the cerebral blood vessels affecting the regional cerebral 
blood flow (Powers and Zazulia, 2010) as age is a risk factor for atherosclerotic disease (Cefalu and 
Wagner, 1997).  
Exclusion criteria for study 
 
Presence of any of the following factors meant that the subjects were excluded from the study: 
1. If a subject had a previous history of an allergic response to NTG, sumatriptan or aspirin. 
2. If a subject was on concurrent anticoagulation with warfarin or a novel anticoagulant.   
3. If a subject was on current treatment with methotrexate.   
4. If a subject had a history of past or current upper gastrointestinal haemorrhage or gastrointestinal 
ulceration.   
5. If a subject had a history of thrombocytopenia or haemorrhagic diasthesis.   
6. If a subject gave a history of significant vomiting as part of their migraine attacks.   
7. If a subject had a ICHD3 beta criteria (Headache Classification Committee of the International 
Headache, 2013) diagnosis of medication overuse headache.   
8. If a subject had continuous or daily headache as it would not be possible to administer NTG to 
trigger a migraine and will also make it difficult to interpret the alterations in cerebral blood flow. 
9. If a subject was pregnant or breastfeeding, they were excluded.   
10.If a subject had active menstruation at the time of the study visit, this was rescheduled.   
11. If a subject had aortic stenosis or significant hypotension (systolic blood pressure<90mmHg or 
<100mmHg and symptomatic) precluding intravenous NTG infusion.   
12. If a subject had obstructive airways disease with previous exacerbation post aspirin, cardiac 






13. If a subject used NSAIDs, aspirin or paracetamol analgesia within 24 hours of each visit, then the 
study visit was rescheduled.  
14. If a subject used regular (greater than 10 days per month) tramadol, codeine or other opioid 
drugs.   
15. Subjects who smoked more than five cigarettes a day or drank more than six cups of caffeinated 
drinks a day were excluded.  
16. Subjects with history of significant mental health disorders were excluded. 
17. Any person unable to lie still within the environment of the fMRI scanner for the required period 
to perform the study were excluded. 
18. When subjects had MRI contraindications (metal implants, pacemaker, brain aneurysm clips 
etc.), they were excluded. Subjects with titanium jaw plate were excluded as it would affect the 
quality of the images. 
19. Any subject unable to understand and follow my instructions were excluded.  
20. Any subject with a history or current use of drugs of abuse were excluded.  
21. Shift workers with altered circadian rhythm were excluded from the study. 
22. Any other condition that in the opinion of the investigator would make the subject unsuitable for 
the study were excluded. 
 
 
 
